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A novel high performance liquid chromatographic assay has been developed for the 
simultaneous determination of isoniazid and N-acetylisoniazid in plasma. Solid phase 
extraction involving C18 columns is used to extract the drug and the metabolite from 
0.5 ml plasma. The analyte peaks are resolved using a CB Spherisorb analytical 
column and ultraviolet detection at 270 nm. The assay is specific to the compounds, 
with consistent recovery of greater than 75% for isoniazid and over 90% for N-
acetylisoniazid . The limits of detection in plasma are 300 ng/ml and 150 ng/ml for 
isoniazid and N-acetylisoniazid respectively. Linearity was conserved down to these 
concentrations. 
This assay was used to generate pharmacokinetic data on 114 tuberculosis patients 
recruited for this study at Brewelskloof hospital, Worcester, South Africa. Using these 
data, various markers were investigated for the determination of acetylator phenotype, 
namely isoniazid half-life, isoniazid plasma level at three hours, and the ratio of 
metabolite to drug at three hours. The ratio of metabolite to drug at three hours proved 
to be the most reliable method for phenotype classification, this being confirmed 
during the genotypic portion of the study. Trimodality was evident, although the non-
discrete separation of intermediate and rapid acetylators made this tentative. 
The mean values of area under the concentration-time curve for each acetylator type 
were found to be significantly different, with rapid acetylators being potentially 
compromised in terms of exposure to isoniazid (slow 32.39 mg.r1.hr, intermediate 
21.25 mg.r1.hr and rapid 16.04 mgJ1.hr). Other pharmacokinetic parameters were 
bimodally distributed, homozygous and heterozygous rapid acetylators forming a 
single acetylator group. Codominance of the rapid and slow alleles was confirmed, the 
estimation of a mean intermediate elimination rate constant being within 7% of the 
observed mean. 
The correlation of genotype to phenotype was found to be 88.2% and the allelic 
distribution was determined to be acceptable using the Hardy Weinberg equation. 
The incidence of raised liver enzyme levels was low in the study population with no 
relation to acetylator phenotype. Age and weight gain after two months of daily 
therapy did not correlate with phenotype. The slow acetylator population comprised of 
12 
a greater proportion of men, while women exhibited twice the number of rapid 
acetylators. No patient factors could be implicated in the apparent discordance of 
phenotype with genotype, and this suggests that there may be new allelic variants in 
this population. 
This report provides validation and proves the usefulness of a novel HPLC plasma-
based assay for determining isoniazid and N-acetylisoniazid levels in patients with 
tuberculosis. 




Having been synthesised by Meyer and Mally in 1912, isoniazid (isonicotinic acid 
hydrazide) was not chemotherapeutically tested until forty years later. 1• 2• 3• 4 
It was introduced as an anti-tuberculosis agent in 1952. Bernstein and Lott et al. 








Figure 1.1 a. The chemical structure of "Nydrazid" 
It was active in mice against the Ravenel strain of M. tuberculosis at a dose of 2 
mg/kg, equivalent to 1/700 that of para-aminosalicylic acid, the therapy of choice at 
that time.3 Grunberg and Leiwant et al. showed efficacy in mice infected with M. 
tuberculosis H37Rv.5 
That same year, Rubin and Hassert et al. 2 published findings on the pharmacology of 
Nydrazid. Using mice, rats and dogs, acute, subacute and chronic toxicity studies 
were performed. The drug was found to be rapidly absorbed from the gastrointestinal 
tract, the early plasma peak drug concentrations being similar when administered 
orally or intravenously. 
Selikoff and Robitzek 1 performed human clinical studies using isonicotinic acid 
hydrazide. Ninety-two patients with tuberculosis were treated with the drug and its 
isopropyl derivative with gratifying effects. Among other improvements significant 
weight gain was noted, as well as the complete elimination of fever in all cases within 
three weeks of treatment initiation. As far as clearing the sputum of the patient, 25% 
were negative after 4 to 15 weeks of therapy; while a further 28% showed a 
significant reduction in smear positivity. Most convincingly, there were no deaths due 
to the progression of tuberculosis, demonstrating the efficacy of these agents in 
human tuberculosis. Until this stage, tuberculosis had only been treated using 
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streptomycin, with the addition of para-aminosalicylic acid to prevent streptomycin 
resistance.6 
Unlike certain other diseases, it was decided very early on that the use of 
monotherapy was a bad treatment choice, engendering the emergence of drug-
resistant tuberculosis. Numerous clinical trials were run, trying to find the most 
beneficial combination of anti-tuberculosis agent for both the patient and the 
disease.6 
Since its introduction, isoniazid has been one of the most powerful chemotherapeutic 
agents used in the treatment of tuberculosis. lsoniazid has remained one of the 
principal components of all first-line drug regimens. It has displayed a relatively low 
toxicity 1 • 2 and is economically viable for third world treament. 7 
Various formulations of isoniazid have been developed with the intent to better drug 
exposure. A significant amount of time and research went into developing matrix 
isoniazid8, a slow release preparation, which would hopefully decrease the number of 
doses required during intermittent therapy, easing the treatment period. However, the 
reduced saturation of the liver enzyme responsible for metabolising isoniazid 
necessitated the dosage to be increased to 40 mg/kg in rapid acetylators.8 Side 
effects in rapid acetylators were more pronounced, due to this increase. It was later 
observed that rapid acetylators fared significantly worse than slow acetylators when 
given ordinary isoniazid with matrix isoniazid during once-weekly intermittent therapy, 
even with an increased dosage.6 This was associated with the observed inhibition of 
the anti-tuberculous activity of isoniazid by the metabolite monoacetylhydrazine 
generated from the matrix isoniazid.9 
The genetic hypothesis of acetylator status has been known since before the 
implementation of the drug in treatment regimens. During studies on the 
pharmacokinetics of isoniazid in the early 1950's, a large interindividual variation in 
metabolism was seen. 10 Initially the acetylation distribution was found to be bimodal, 
but more recent research has proven it trimodal , making a definite distinction 
between heterozygous and homozygous rapid acetylators, confirming initial 
expectations by Sunahara 11 and Dufour12 This work has been studied extensively 
and confirmed by genetic work beginning on twins and families in the early 1960's, 13 
but progressing at a phenomenal pace in the beginning of the last decade. 
Apart from dealing exclusively with isoniazid and acetylator status; there are many 
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other drugs associated with this polymorphism. These include caffeine, 
procainamide, hydralazine, enflurane, dapsone, and sulphadimidine.14·15 Various 
methods exist for the determination of acetylator phenotype. reviewed in 16 
The isoniazid17• 18• 19• 20• 21 and sulphadimidine 17• 22• 23 tests were the first to be used 
regularly. Price-Evans and White (1964) used isoniazid half lives for phenotyping but 
later, sulphadimidine replaced isoniazid because it was easier and required less time 
to determine acetylator status using one sample of either plasma or urine.23 
However, it was shown that urine testing left larger room for error than blood 
sampling. Du Souich and McClean et a/.24 highlighted this as well as a number of 
changes in nonmetabolic parameters, which could affect phenotyping using urine 
sampling with sulphamethazine and other agents, as opposed to a 6 hour blood 
sample. 
Caffeine has been used as a metabolic probe to test for NAT2 acetylator phenotype. 
Acetylator phenotype is measured by determining the peak height ratio of two 
caffeine metabolites, using high performance liquid chromatography.25 This test has 
often been compared to those using sulphasalazine25 and sulphadimidine26 , and has 
been shown to produce identical results. 
The types of assays, which have been used to assay biological samples, include 
colorimetric and high performance liquid chromatographic systems. Both have shown 
equivalent efficiency. The dapsone method27 has been used frequently for 
determining acetylator status. This method can easily be implemented in both the 
clinical as well as the population screening setting. The method for phenotyping 
relies on the ratio of monoacetyldapsone to dapsone in plasma, and this remains 
constant in the bloodstream for up to 48 hours. Thus the timing of the sample need 
not be precise.16 The assays used include HPLC methods, but also a number of 
other chromatographic methods. The question then was whether acetylation 
occurred bimodally or trimodally. 
Today it is generally accepted that the distribution is trimodal, genetically and 
phenotypically, but the separation between the heterozygous rapid from the 
homozygous rapid acetylators tends not to be as discrete as that between the 
homozygous slow and the other two types.28 
lsoniazid is still today regarded as an extremely powerful weapon against 
tuberculosis, in terms of its early bactericidal activity (EBA = 0.72).7• 29 The maximal 
levels attained after a standard dose has been observed to be 16 times higher than 
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the minimal inhibitory concentration (MIC), much higher than that for other agents.7 
Thus, a decrease in plasma levels should not affect the overall killing ability 
significantly, provided that the decrease is slight. In the absence of kinetic vs. 
outcome-related studies, application of absolute levels to clinical outcomes is difficult. 
Many different populations have been subjected to acetylator phenotyping, with 
evidence of certain population trends, such as the predominance of rapid acetylators 
in people of Asian descent. This epidemiology was later applied to genotypic 
analysis, linking various mutant alleles to certain origins.30 
Table 1.1 i. The acetylator phenotype distribution in various populations using 
isoniazid 
~lllf:Hhlil t;,i,r,:nre1~~1~,e:1..-1111~""1 .............. •!.ll lellf!.J 
I % Slow % Intermediate % Rapid 
Japanese 11.5 44.4 44.1 Sunahara and Urano et al. 1961 11 
Thai 27.8 52.8 19.5 
Ainu 12.8 36.0 51.2 
Korean 10.8 44.6 44.6 
Ryukuyuan 14.5 51.6 33.9 
Caucasian 58.10 35.24 6.67 Dufour and Knight et al. 19641£ 
American 
Black American 50.86 43.96 5.17 
Japanese 9.57 38.76 51.67 
Ethiopian 83.0 - 17.0 Russell and Russell 1973j1 
Amharas 
Lapps 28.57 - 71.43 Ellard and Gammon et al. 1973jL 
Lapps 37.0 - 63.0 Tiitinen and Mattila et al. 1973jj 
Finns 56.0 - 44.0 
Black South 27.0 - 73.0 Buchanan and Strickwold et al. 
Africans 197620 
West Africans 40.0 - 60.0 Salako and Aderounmu 1977.,,. 
Japanese 86.84 - 13.16 Horai and lshizaki et al. 1982'"' 
Indians 58.66 41.33 Gurumurthy and Krishnamurthy et 
al. 198436 
South African 35.0 45.0 20.0 Parkin and Vandenplas et al. 
Coloured 199737 
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1.2. BREWELSKLOOF HOSPITAL 
Brewelskloof hospital is situated just outside Worcester in the Breede Valley, north of 
Cape Town. Not officially designated as a tuberculosis hospital, it has become 
devoted to caring largely for patients with TB. It is a poor facility with few resources, 
but still manages to deal with the ever-increasing load of tuberculosis sufferers. 
In the beginning of 1999, the Department of Pharmacology, University of Cape Town 
was approached to assay TB drug levels from a selected group of patients at 
Brewelskloof hospital. It had been noted that the relapse rate/treatment failure rate 
was increasing, and the investigation into this began at the level of medication 
efficacy. 
Following this, the Department of Pharmacology, in collaboration with the hospital, 
initiated a pharmacokinetic study, the aims of which included determining the 
relationship betweeA the pharmacokinetics of anti-tuberculosis therapy and treatment 
outcome. This acetylator status study formed part of the patient characteristics 
determination, and assessing their role in the pharrnacokinetics of anti-tuberculosis 
drug therapy. 
This work is still ongoing, with the hope to follow up all patients meeting research 
criteria up to two years, in order to gauge response, via certain study-determined 
markers. 
Figure 1.2a. Brewelskloof Hospital, Worcester, Breede River Valley. 
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AIMS 
The aim of this study is to develop the means to produce a comprehensive acetylator 
status study of in-patients at Brewelskloof hospital, producing criteria for phenotyping 
and validating the technique by genotypic analysis. 
OBJECTIVES 
1. Develop a high performance liquid chromatography plasma-based assay for the 
simultaneous determination of isoniazid and N-acetylisoniazid. 
2. Conduct the pharmacokinetic study at Brewelskloof hospital, producing 
pharmacokinetic data on 100+ tuberculosis patients. 
3. Use pharmacokinetic markers of isoniazid and N-acetylisoniazid to determine 
acetylator phenotype of patients, viz; half-life, Cmax, AUCI, AUCT and 
INH:AclNH ratio at 3 hours. 
4. Compare acetylator phenotype obtained by each marker with the NAT2 genotype 
of the respective patient. 
5. Compare acetylator phenotype obtained with clinical response and toxicity. 




Numerous methods to determine isoniazid and N-acetylisoniazid have been 
developed and published since the introduction of isoniazid. Various assay types 
have been implemented, such as high performance liquid chromatography, 
fluorometry and colorimetry. 
Ellard and Gammon developed methods of determination in serum and in urine, 
working from various other methods already published.38 lsoniazid and N-
acetylisoniazid were determined via fluorometry and colorimetry, one being more 
specific at low concentrations of isoniazid, and the other at higher concentrations. 
Utilising chemical methods to derivatise and extract compounds, extremely sensitive 
assays were produced, allowing very low concentrations to be analysed, but the 
efficiency is encumbered by a long assay procedure, using many different reagents. 
Svensson and Muchtar et al. published a method, which utilised ion pair high 
performance liquid chromatography to determine the concentrations of isoniazid and 
N-acetylisoniazid in plasma and urine.39 They originally designed this method 
because they experienced reduced sensitivity and found the spectrophotometric 
method to be time-consuming. The extraction procedure employs ultrafiltration, a 
simple technique used to rid the sample of unwanted protein contaminants. The 
method produced a simultaneous detection of isoniazid and N-acetylisoniazid. It does 
involve a derivatisation step, converting isoniazid into propionylisoniazid, before 
resolving the compounds on a reverse phase HPLC analytical column, using 1-
dodecylsulphate as a counter ion. 
Fluorescence detection is commonly used in the determination of isoniazid in 
biological samples. loannou40 developed a simplified technique for the fluorometric 
detection of isoniazid and N-acetylisoniazid. However, the detection of N-
acetylisoniazid was indirect in that total hydrazides were measured after acid 
hydrolysis. This would not be adequate for the proposed study. 
Methods have been described for the liquid phase extraction of isoniazid and N-
acetylisoniazid from plasma. Hutchings and Monie et al. described a comprehensive 
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method for the recovery of these two compounds from heparinised plasma.41 The 
method is not excessively time-consuming and provides adequate recoveries. The 
detection system includes ultraviolet detection at 266nm, resolving both peaks in a 
single run on HPLC, using a nitrile analytical column, in a mobile phase of (0.01 M) 
phosphoric acid in acetonitrile : water (20:80). 
Figure 2.1a. The chemical structure of isoniazid 
Figure 2.1 b. The chemical structure of N-acetylisoniazid 
Although a number of methods exist for measuring isoniazid and N-acetylisoniazid 
levels in plasma, it was necessary for the purposes of this study to develop a 
method, which would allow assaying of a large number of samples in a relatively 
short period of time. This would facilitate the speedy generation of pharmacokinetic 
data. The ideal option would be to avoid time-consuming steps such as 
derivatisation and acid hydrolysis. A method of choice would allow the simultaneous 
extraction of both drug and metabolite, coupled with a simultaneous resolution on 
HPLC. 
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2.2. MATERIALS AND METHODS 
Materials 
lsoniazid (INH) (Batch no. 960805) was obtained from Hoechst Marion Roussel 
(Johannesburg, South Africa). A standard of N-acetylisoniazid (AclNH) was generously 
donated by Dr Gordon Ellard, which he had prepared personally. HPLC-grade acetonitrile, 
methanol and trifluoroacetic acid (TFA) were purchased from Merck (Darmstadt, Germany). 
Deionised and distilled water was obtained via a Milli-Q Water system. C18 BondElut 
extraction columns were purchased from Analytichem International (Harbour City, CA, USA). 
HPLC equipment consisted of a Spectra-Physics (San Jose, CA, USA) set-up, comprised of a 
pump Model SP8800, a degasser SCM400, an autosampler SP8780 and an integrator 
SP4290, which was ultimately connected to a variable wavelength UV detector Linear UVIS 
200 Model 0200-4000 Linear Corp (Reno, NV, USA). 
Methods 
HPLC resolution was developed using the method described in the publication by Smith and 
Van Dyk et a/.42 The method uses a mobile phase system consisting of 3% acetonitrile in 
0.06% TFA. A reversed phase C8 analytical column (Spherisorb, 150 X 4.6 mm ID, 5 µm -
Supelco, USA) linked to a C8 precolumn was used with a flow rate of 1.5 ml per minute. UV 
detection was at 270 nm. The retention time for isoniazid varied between 2.80 and 3.00 
minutes. This method was altered in various ways, including flow rate, mobile phase 
composition and pH to optimise the set-up for the simultaneous resolution of isoniazid and N-
acetylisoniazid. 
Sample preparation began with adopting the form of solid phase extraction as per the 
method of Smith and Van Dyk et a/.42 Working with plasma, the blood collection was 
performed using Vacutainer PST™ Gel and lithium Heparin tubes, which were immediately 
placed on ice before being spun down at 3 000 rpm to pellet the erythrocytes. Centrifugation 
occurred within 15 minutes of collection and the plasma was stored at -80°C until required. 
BondElut C18 extraction columns were washed twice with 2 ml HPLC grade methanol, 
followed by two washes of 2 ml water and 2 ml 0.05 M potassium phosphate (pH 4.5) 
(phosphate buffer). This served to precondition the columns, facilitating the binding of applied 
drugs. Five hundred microlitres of plasma was thawed and loaded onto each column. This 
was allowed to bind for 5 minutes and the unbound material was pulled through and 
discarded. The columns were then washed again with 1 ml 0.05 M phosphate buffer, 
removing excess plasma and unwanted waste. The bound drugs were then eluted with 0.5 
ml acetonitrile and 0.5 ml methanol, the eluents subsequently being pooled. Of this, 500 µI 
was evaporated down to dryness using a Vacuum centrifuge at 37°C for 60 minutes and 
reconstituted in 500 µI 3% acetonitrile in 0.06% TFA. Twenty microlitres was then injected 
onto the HPLC for resolution . lsoniazid and pyrazinamide were detected together on the 
same system at 270 nm. 
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The method of Hutchings and Monie et al. 
41 utilises a liquid phase extraction. One millilitre 
of spiked plasma is placed into a glass test tube. Five hundred microlitres of 0.5M phosphate 
buffer (pH 7.4), saturated with sodium chloride, is added to this. The sample is extracted 
using a mixture of 10 ml chloroform:butane-1-ol (70:30) (AnalaR, BDH Lab supplies), while 
gently mixing for 10 min. The mixture is separated by centrifugation at 3 000 rpm for 6 
minutes. The top layer is then aspirated and the coagulated protein layer removed. Back 
extraction of the organic layer is performed using 500 µI phosphoric acid, mixing for 10 min. 
Two hundred microlitres is then injected onto the HPLC. 
Stock solutions of both compounds were prepared in water and stored at -80°C in aliquots of 
100µ1. The plasma to be spiked was supplied by the Blood Transfusion unit at Groote Schuur 
Hospital and maintained at -20°C until required . Thawing took place at room temperature. 
The plasma was then vortexed (Vortex-Genie-2, Scientific Industries) and spun down at 3 
OOOrpm for 6 min in a bench top centrifuge (Sigma 3E-1) to remove the fibrin and other 
particulate matter. Aliquots of 500 µI plasma were spiked with the standard stock solutions, to 
a final concentration of 10 µg/ml for each drug. Various methods of extraction were initially 
investigated , including liquid and solid phase extraction. 
Method optimisation involved running 10 µg/ml standards of each analyte on the system 
described above. HPLC methods required changing the concentration of acetonitrile, altering 
the percentage TFA used, thus altering the pH of the mobile phase, changing the ratio of TFA 
to acetonitrile and altering the flow rate. Sample preparation methods required investigation 
into the preconditioning and washing buffer and the elution solvents. Having developed a 
potential assay system, tests such as storage stability, temperature stability, recovery 
analysis, sensitivity, detection limits and linearity were performed. 
Assay validation was performed in order to test the accuracy and efficiency of the developed 
assay. Attributes such as specificity, recovery, stability (related to temperature), linearity, 
standard curves and sensitivity were investigated. 
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2.3. HPLC RESOLUTION 
2.3.1. RESULTS 
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The method of Smith and Van Dyk et a/.42 was applied in an attempt to resolve the 
standards of isoniazid and N-acetylisoniazid prepared in mobile phase. Using a 
mobile phase of 4% acetonitrile to 96% (0.06%) TFA solution on a CB analytical 
column, resolution of the two compounds was not achieved. N-acetylisoniazid was 
not retained adequately on the column. 
In an attempt to increase the retention times of both analytes, the concentration of 
acetonitrile was reduced to 1 %, while the pH remained unchanged. This only served 
to shift both peaks later, and did not improve the resolution. 
The pH of the mobile phase often affects the retention times of specific compounds. 
Different concentrations of TFA were used to vary the pH and to gauge the effect of 
pH on the elution of drug and metabolite. 











Using a mobile phase of CH3CN : 0.15% TFA (1 :99) the pH of the TFA solution 
played a large role in determining the retention time of N-acetylisoniazid. N-
acetylisoniazid was affected more than isoniazid when the pH was lowered, as is 
seen when comparing the relative retention times above. The change in retention 
time for isoniazid was +0.5 min, compared to a change of +1.76 min for N-
acetylisoniazid . 




Figure 2.3.1a. A standard of 2.5 µg/ml isoniazid (4.01 min) and 2.5 µg/ml N-
acetylisoniazid (4.59 min) in 1% CH3CN:99% (0.15%) TFA at pH 1.75 at OD21onm· 
2.3.2. DISCUSSION AND CONCLUSIONS 
The CB reverse phase analytical column, when used with a mobile phase of pH 1.75, 
resolved the two peaks. 
This demonstrated the increased sensitivity of N-acetylisoniazid to a lower pH. When 
running at a pH of 1.9, the N-acetylisoniazid is eluted before the isoniazid (Table 
2.3.1a.). After adjusting the pH to 1.75 by increasing the strength of the TFA solution 
the order of elution was reversed. lsoniazid displayed a retention time of 3.91 min, 
which was followed by N-acetylisoniazid at 4.49 min. 
Since isoniazid has one of its pKa values at 1.8,43 going below this pH will produce a 
protonated form of isoniazid. Above pH 1.8, the compound will have a negative 
charge associated with the loss of a proton from the carboxyl group. 




Figure 2.3.1 c. The protonation of isoniazid relative to the first pKa value. 
The pKa values of N-acetylisoniazid are not known. However, it is clear that lowering 
the pH to 1. 75 significantly increased the retention of the compound when compared 
to isoniazid. The central structure of N-acetylisoniazid consists of a pyridine ring 
(Figures 2.1 a and 2.1 b ). The structures differ at the substituted group at C1. It is 
most likely due to this structure that N-acetylisoniazid responds better to a pH 
reduction. The substituted group in N-acetylisoniazid is an ether, while in isoniazid it 
consists of a primary amine and a secondary amide.14•15 The presence of the two 
carbonyl groups in N-acetylisoniazid could be the cause of the heightened pH effect, 
the carbonyl groups being responsible for the increased resonance withdrawal of pi 
electrons, thereby deactivating the aromatic ring to a greater extent that in 
isoniazid.44 
The two carbonyl groups, now in possession of greater electronegative force, would 
exert a greater inductive effect on the CB carbon chains in the column, producing a 
positively charged carbon atom, allowing the compound to adhere more strongly, and 
be eluted later. Of course, this would all depend upon the exact pKa values 
associated with the functional groups in question. 
Using a CB Spherisorb Analytical column and a mobile phase comprised of CH3CN 
(1): 0.15% TFA (99), peaks were well resolved, producing adequate resolution at 10 
µg/ml concentration. (See figure 2.3.1a.). 
The use of low pH in mobile phases may have previously been cause for concern 
due to the instability of the silica at low pH. However, in recent years a wide range of 
HPLC analytical columns with stability in the pH range 1-13 has been produced. 
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2.4. SAMPLE EXTRACTION 
Various methods of sample extraction from plasma were attempted, with varying 
degrees of success. Ultimately, the extraction procedure used by Smith and Van Dyk 
et a/.42 was modified for the analysis of N-acetylisoniazid. 
Pooled drug free plasma was spiked with known concentrations of isoniazid and N-
acetylisoniazid. In order to determine the optimum extraction procedure, it was 
decided to concentrate on the extraction of N-acetylisoniazid initially, the method for 
isoniazid already established. 
2.4.1. RESULTS AND DISCUSSION 
The solid phase extraction method of Smith and Van Dyk et al. was attempted initially 
for extracting isoniazid and N-acetylisoniazid simultaneously from 1 ml spiked plasma 
(Section 2.2). The results presented in table 2.4.1 a below indicate that N-
acetylisoniazid fails to bind adequately to the C18 extraction columns. 
Table 2.4.1a. The recoveries of INH and AclNH, using the extraction method of 
Smith and Van Dyk et a/.4 2 
Analyte Peak Area Peak Area Recovery 
(10µg/ml) (M obile Phase) (Plasma) (%) 
INH 487 125 271 690 56.16 ± 0.38 
AclNH 0 0 0 
In an attempt to improve the binding of both analytes, the pH of the plasma was 
lowered with 5M HCI and the pH of the preconditioning buffer was altered. This 
failed to improve the binding of either compound. 
Liquid phase extraction, using the method of Hutchings and Monie et a/.41 (see 
section 2.2) was attempted. The high concentration of NaCl successfully precipitated 
most of the protein out of the plasma, forming a large mass at the interface of the 
aqueous and the organic layers. Both the isoniazid and N-acetylisoniazid were 
extracted into the chloroform:butan-1-ol mixture, but with unsatisfactory recovery. 
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The recovery of isoniazi d reached 85.29%, but the N-acetylisoniazid recovery 
b.). remained low {Table 2.4.1 
Table 2.4.1 b. The reco 
extraction method of Hutc 
Analyte 
veries of isoniazid and AclNH using the liquid phase 
hings and Monie et a/.41 
Peak Area Recovery 
(10µg/ml) (M 
Peak Area 
obile Phase) (Plasma) (%) 
INH 498 358 305 267 61.25 
AclNH 315 022 9 455 3.00 
INH 498 358 425 054 85.29 
AclNH 315 022 51 874 16.47 
It is clear that this method i mproved the recovery of N-acetylisoniazid, but the results 
llowing this, assay development returned to solid phase were still unacceptable. Fa 
extraction. 
In order to establish if N-acetylisoniazid was being removed from the solid phase 
ashing buffer, the wash step was eliminated. Modifying the 
onditioninglwashing buffer pH had failed to produce a 
extraction column by the w 
plasma pH and the prec 
significant increase in yiel d of both drugs. Varying the pH of the washing buffer failed 
to retain the compound. 
Following the elimination 
column, significant recove 
of a buffer wash after applying the spiked plasma to the 
ries of N-acetylisoniazid were recorded. This showed that 
binding strongly enough to withstand a buffer wash. N-acetylisoniazid was not 
Analysis of the buffer was hes confirmed that a major loss of N-acetylisoniazid was 
overies from plasma after eliminating the buffer wash step 
7.37; cr = 3.81 %) (Table 2.4.1 c.). Adjustment of the pH of 
application to the column had no effect on yield. 
occurring at this step. Rec 
exceeded 50% (Mean = 5 
the spiked plasma prior to 
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Table 2.4.1 c. N-acetylisoniazid recoveries using different preconditioning buffers 
Buffer pH RT (min) Peak Area Recovery(%) 
1.5 5.36 166 622 57.57 
3 5.41 145 978 50.43 
5 5.37 176 391 60.94 
7 5.39 175 899 60.77 
8 5.38 165 377 57.14 
STD in MP 5.35 289 438 100.0 
Preconditioning the columns with a range of pH buffer at different pH's prior to the 
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Figure 2.4.1 a. The effect of various buffers on the recovery of isoniazid (n=S, Mean ± SEM). 
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Figure 2.4.1 b. The effect of various buffers on the recovery of N-acetylisoniazid (n=5, Mean ± 
SEM). 
Recovery was maximised using water for preconditioning instead of a phosphate 
buffer. The mean recovery of isoniazid when using water as the preconditioning wash 
and eliminating any subsequent washing, was 82.87% ± 1.453% and 91.98% ± 
2.858% for N-acetylisoniazid. 
Elution of the drugs from the solid phase extraction columns without inclusion of a 
wash step frequently resulted in some protein precipitate in the eluate. This was 
removed by centrifugation and the supernatant used for analysis. 
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The HPLC program set up to elute isoniazid at 4.00 minutes and N-acetylisoniazid at 
4.50 minutes at a flow rate of 1 ml/min, following solid phase extraction was as 
follows: 
Table 2.4.1d. Program set up on the ternary HPLC pump including end-of-run wash 
Time (min) % (100%) CH3CN % (0. 15%) TFA 
0.0 1.0 99.0 
4.0 1.0 99.0 
5.0 20.0 80.0 
9.0 20.0 80.0 
10.0 1.0 99.0 
13.0 1.0 99.0 
The figures shown below (figures 2.4.1c., 2.4.1d. and 2.4.1e.) indicate the results of 
application of the solid phase extraction method determined above, coupled with the 
HPLC resolution method described in section 2.3. The peak appearing after 5 
minutes represents the extraneous plasma proteins being washed off the column by 
the 20% acetonitrile wash. The run time of the assay was determined using the flow 
stability gauge to determine when the flow has returned to an acceptable level of 
stability following the acetonitrile wash (20%). A flow stability of below 10 was 
determined adequate and this was observed in the consistency (i.e. steady baseline 
and uniform retention times) of the subsequent assays. 
The blank sample shown in the figure below (Fig. 2.4.1 c.) indicates an interfering 
plasma peak, which merged with the isoniazid on occasion. Running an extracted 
blank plasma sample with each patient set enabled an integration correction to be 
made to the reported peak area of isoniazid, when this peak did not separate. 
















Figure 2.4.1d. An extracted control of 2.5 µg/ml isoniazid (4.00 min) and 2.5 µg/ml N-
acetylisoniazid (4.57 min). 
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2.4.2. FINAL CONCLUSIONS 
An assay procedure has successfully been implemented which includes a simple 
solid phase extraction, simultaneous extraction of isoniazid and N-acetylisoniazid, 
which are then detected on the same HPLC system. 
HPLC RESOLUTION 
• Column: S5 CB Spherisorb (25cm X 4.6mm I.D.; 5µm particle size) 
• Mobile Phase: CH3CN (1): 0.15% TFA (99)- pH 1.75 
• Flow Rate: 1.00 ml/min 
• Run Time: 13.0 min 
• Wavelength: 270 nm at 0.02 a.u.f.s. deflection 
• A two minute wash using 80% acetonitrile is implemented after 5 minutes to clean 
up the column for the following injection. 
• The integrator chart speed was set to 0.5 and the peak threshold at 200, setting a 
cut off limit of a peak area of 200. 
SAMPLE EXTRACTION 
1) Wash each SPE C18 column with methanol and water. 
2) Precondition each column with 1.0 ml Milli-Q water. 
3) Apply 500 µI plasma to each column, pull onto the column and allow to bind for 5 
min. 
4) Pull the plasma through the columns with the vacuum until dry. 
5) Elute into labelled, clean, dry polypropylene tubes with aliquots of CH3CN as 
follows: 
• 200 µI left for 2 min and eluted (repeated), 
• 100 µI left for 1 min and eluted. 
6) Spin down eluent at 10 000 rpm for 5 min, to pellet the protein precipitate. 
7) Remove 250 µI supernatant and transfer into a screw-capped glass vial, which 
has been acid-washed. 
8) Evaporate the samples completely in a rotary evaporator at 37°C (± 45-60 min 
depending on the pump strength). 
9) Reconstitute with 500 µI mobile phase, incurring a two-fold dilution. Vortex and 
inject 20 µI onto HPLC. 
Coupled with the solid phase extraction method determined earlier, the wash was 
sufficient to clear up problems with protein-contaminated samples. 
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2.5. ASSAY VALIDATION 
In order to create a working assay system, it is necessary to run a series of validation 
steps using the assay. Having set up the assay it was validated with respect to 
detection limits (or sensitivity); linearity; specificity; recovery; precision and 
stability. 
2.5.1. RESULTS AND DISCUSSION 
2.5.1.i. A Standard curve was constructed by spiking aliquots of drug free 
plasma with known concentrations of isoniazid and N-acetylisoniazid. Samples were 
simultaneously spiked with isoniazid and N-acetylisoniazid from 10 µg/ml down to 
0.03125 µg/ml, extracted and analysed using the predetermined assay system 
(sections 2.3 and 2.4). Following this, linear regression curves were constructed 
using Graph Pad Software Prism (Version 2.01) and the equations calculated. 
Standard Curves 











0.0 2.5 5.0 7.5 10.0 12.5 
Concentration (µg/ml) 
• INH 
,2 = 0.9948 
Mean o/CV = 9.854 
• AclNH 
,2 = 0.9992 
Mean o/C,V = 7.96 
Figure 2.5.1 i. Standard curves for isoniazid and N-acetylisoniazid. (n = 6) 
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Each point was prepared by serially diluting a stock solution of 10 µg/ml. The 
resulting curves demonstrated good linearity (r = 0.9948 and 0.9992 for isoniazid 
and N-acetylisoniazid respectively within the range of concentrations tested. 
lsoniazid: y = 27170x + 2 911 
N-acetylisoniazid: y = 41 060x - 10 660 
The equations from each curve may be used to convert peak areas of unknown 
concentration, into useful data. The coefficients of determination for each curve 
provided an estimate of the linearity of the assay. Both of these are above 0.990 so 
the assay was determined to be linear. 
2.5.1.ii. Detection Limits were determined by extending the range of the 
standard curve down to 75 ng/ml for both compounds. Having completed this 
experiment in plasma, it was repeated in mobile phase. This was to determine the 
effect of any interfering plasma peaks. Peaks that were clearly visible and 
successfully integrated at the lowest recordable concentration, were determined to 
be the detection limit for that analyte. The data was plotted using GraphPad Prism 
(Version 2.01 ). Linearity was determined again using the same set of experiments. 
An estimation of linearity was gleaned from the resulting coefficient of determination 
for each analyte for each curve. The coefficients of determination were 0.9911 for 
isoniazid and 0.9927 for N-acetylisoniazid. These values compare closely with that 
obtained in the previous experiment (section 2.5.1.i). The experiment was performed 
in triplicate for each set of conditions. 
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Detection Limits and Linearity 
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Detection Limits and Linearity 
Mobile Phase Extraction 
Detection limit: 
INH = 150 ng/ml 
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Figure 2.5.1.iib. Sensitivity and linearity testing using extraction from mobile phase. (n = 3) 
The figures above indicate that even at lower concentrations, the linearity is 
maintained, making this assay suitable for determining pharmacokinetic curves in 
patients. The purpose of extracting from mobile phase is to exclude any interference 
offered by extraneous plasma peaks during sensitivity analysis. 
The assay was shown to be linear, coefficients of determination of 0.9911 and 
0.9927 for isoniazid and N-acetylisoniazid respectively (Figures 2.5.1 .iia.). Each 
point was determined using a set of three samples, constructing a curve from 6 
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concentration points, including zero, over the concentration range 10 µg/ml to 600 
ng/ml for isoniazid and 300 ng/ml for N-acetylisoniazid. 
The plasma detection limits (figure 2.5.1.iia.) were easily distinguished, with N-
acetylisoniazid being more distinguishable than isoniazid at lower concentrations, 
due to the absence of plasma peaks at the later retention time. As long as the peak 
was clearly visible and successfully integrated, it was determined successfully 
detected. A lower limit of 300 ng/ml was observed for isoniazid and 150 ng/ml for its 
metabolite using plasma extractions. Excellent linearity was observed even at these 
low concentrations (i.e. r2 above 0.99). 
2.5.2.iii Temperature stability was deduced using a set of experiments 
designed to decide upon optimal storage conditions (figures 2.5.1.iia. and 2.5.1.iib.) 
for patient plasma samples. A stock plasma solution at 5 µg/ml of both analytes was 
prepared and aliquotted to minimise damage by the freeze-thaw process, and stored 
at various temperatures for up to 72 hours. Room temperature (±21 °C), 4°C, -20°C 
and -80°C were selected. Each day, three aliquots were removed, extracted and 
analysed using the predetermined assay method. Recoveries were calculated and 




c: :::- 5.o- --m 
:8 -E :: rn n, C) .. ::: 
~ ~ H m 
INH Temperature Stability 
(n=3) 
G) 2 5- : : m 
l . HI; 
0·0 ....L..C..,;, ..... o.... o""'oo ....... ___._:....i....i.;.; ............ 
--1 
24.000 48.000 72.000 
Time (hours) 





Figure 2.5.1.iiia. lsoniazid temperature stability. (n = 3) 
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Figure 2.5.1.iiib. N-acetylisoniazid temperature stability. (n = 3) 
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Both isoniazid and N-acetylisoniazid are stable at -B0°e, without adding any 
stabilising agents to the plasma. The stability over three days was acceptable without 
the addition of any stabilising agents. The other temperatures indicate marked 
degradation in both analytes. 
Up to 72 hours, the stability of isoniazid at -B0°e was adequate. The general stability 
of N-acetylisoniazid was considerably reduced at temperatures above -B0°e, 
compared to that of isoniazid. This was most likely because the standards were 
supplied by different sources. From this set of experiments, it is clear that the optimal 
storage option would be at -B0°e, with no additives. Some researchers add 
chemicals to the plasma samples to promote preservation, such as a crystal of 
thymol17 or ascorbic acid45, but these samples were seen to be stable without any 
such addition. 
2.5.1.iv. To determine storage stability pooled stocks of 10 µg/ml (isoniazid 
and N-acetylisoniazid) plasma samples were aliquotted and stored at -B0°e for up to 
B days. Each day, a set of four was removed, extracted and analysed. Recoveries 
were calculated and signs of deterioration were noted. 
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Figure 2.5.1.iv. Analyte stability at-80°C. (n = 4) 
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The mean coefficients of variation were calculated as 4.43% for isoniazid and 2.63% 
for N-acetylisoniazid. Since this experiment began with one pooled solution of spiked 
plasma, the only factors contributing to variation could be the storage temperature, or 
daily variation. The results show clearly that both analytes are stable in plasma at -
80°C for at least 8 days. 
2.5.1.v. Precision was estimated using a similar set of experiments. 
Coefficients of variation (%) were monitored throughout the validation series of 
experiments. Reproducibility may also be established by considering the 
coefficients of variation. Care was taken in monitoring these during every test 
performed. It was noted that these remained under 10% during each experiment, 
determining the assay in terms of being reproducible. 
2.5.1.vi. Specificity was determined using a number of other drugs, known to 
be common concomitant medications in TB patients. This was done knowing that the 
population to be sampled for the phenotypic data consisted of sick TB patients, many 
on different concomitant medications. The drugs tested were kanamycin (Sigma), 
amikacin (Sigma), thioacetazone (Sigma), ethionamide (Sigma), pyrazinamide 
(Hoechst Marion Roussel), rifampicin (Hoechst Marion Roussel) and para-
aminosalicylic acid (Sigma). A set of 10 µg/ml plasma samples (containing both 
isoniazid and N-acetylisoniazid) were prepared. To each sample, an aliquot of each 
drug was added to a final concentration of 10 µg/ml. These were then analysed and 
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run on the HPLC with a corresponding 10 µg/ml standard of each drug, separately. 
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Recovery with other drugs 
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Figure 2.5.1.vib. lsoniazid and N-acetylisoniazid recovered from plasma spiked with other 
drugs, expressed as a percentage of the standard run in mobile phase. (n = 6) 
(std = alone; mix= with other drugs) 
The results of the assay specificity (figures 2.5.1.via. and 2.5.1.vib.) tests were 
conclusive. It was clear that not one of the other drugs, all of which are commonly 
given as concomitant medication to tuberculosis patients, produced an interfering 
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peak or inhibited drug recovery. The only drug that produced a small peak upon 
HPLC analysis was thioacetazone, but this was as a standard in mobile phase at 
3.48 minutes. Once extracted, this peak was not evident. The recovery was highly 
reproducible compared to the previous recovery determination. Mann Whitney tests 
(two-tailed at 95% Cl) showed no significant difference between the recoveries 
obtained for the mix (with additional drugs) and standard (isoniazid and N-
acetylisoniazid alone) sets. 
2.5.1.vii. Recovery was also determined experimentally prior to patient sample 
analysis. This was done using standards in mobile phase and spiked plasma 
samples. Each plasma sample was spiked with 10 µg/ml isoniazid and N-
acetylisoniazid, extracted and run with a corresponding standard in mobile phase. 
After correcting for the dilution factor of 2, implemented during the extraction process, 
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C:::::::::::::: INH: 76.78% ± 2.561 
%CV= 5.78 
m:m:mll AclNH: 91 .99% ± 3.449 
o/rCV = 6.49 
Figure 2.5.1.vii. Recovery analysis. (n = 4) 
Analyte recovery (figure 2.5.1.vii.) is a good indication of assay quality. Certain 
drugs are known to give poor recoveries, but as long as the reproducibility is of a 
high standard, the assay is useful. In the method by Smith and Van Dyk et al.,42 the 
recovery of isoniazid (>70%) may be viewed as being low, but the results are highly 
reproducible and thus give accurate estimations of drug levels. The results show that 
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the recoveries, apart from being acceptable (76.78% for isoniazid and 91.99% for N-
acetylisoniazid), were also shown to be consistent over the concentration range 5 
µg/ml to 1.25 µg/ml , with coefficients of variation of 5.78% and 6.49% for isoniazid 
and N-acetylisoniazid respectively. It may be noted that recoveries become less 
reproducible at lower concentrations (i.e. 1.25 µg/ml; figure 2.3.1.vii), yielding larger 
error bars, but are still within the limits of acceptability. The curves set up to 
determine linearity (figures 2.5.1.iia. and 2.5.1.iib.) did indicate linearity at lower 
concentrations, with acceptable coefficients of determination. 
2.5.2. FINAL CONCLUSIONS 
Thus, from the experiments above, this assay may be deemed successful and useful 
in terms of its reproducibility, specificity, recovery, sensitivity, linearity and stability. 
The assay is acceptable in terms of the coefficients of determination (all above 
0.990) and coefficients of variation (all below 10%). The recoveries are acceptable 
because they are consistent, all achieving yields of above 70%. 
In terms of the objectives prior to setting up the assay, those being primarily time and 
quality, these have been successfully achieved for the purposes of determining 
pharmacokinetic data for 100+ tuberculosis patients. 
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CHAPTER THREE 
PHARMACOKINETICS AND ACETYLATOR STATUS 
3.1. INTRODUCTION 
42 
lsoniazid (isonicotinic acid) is bactericidal for intra- and extra-cellular mycobacteria as 
well as mycobacteria in closed caseous lesions. The mechanism of action involves 
the inhibition of mycolic acid synthesis in the mycobacterial cell wall.46 It is 
administered to treat tuberculosis, as well as preventative therapy. 
The pharmacokinetics of isoniazid are well known. lsoniazid may be administered 
orally or intravenously. When administered orally, it is absorbed rapidly and 
completely within 2 hours of administration.15• 47 Food and antacids are known to 
prolong absorption. Bioavailability is significantly reduced by first-pass metabolism. 
Maximum concentrations reach an average of between 3-5 µg/ml at approximately 1-
2 hours.14 lsoniazid is a polar drug, the volume of distribution being comparable to 
that of total body water in all tissues and fluids including CSF, and falling in the range 
of 0.6-0.7 L/kg.8 The half life of this drug differs between individuals according to 
acetylator status and may range from 0.5-1.6 hours in rapid acetylators and 2-5 
hours in slow acetylators. Less than 10% of the drug is protein bound. 14• 15 
The rates at which individuals convert isoniazid to metabolites devoid of any anti-
tubercular activity differ greatly between individuals, although they do remain 
constant within that individual.15 The determining factor in isoniazid the rate of 
elimination of isoniazid is the rate of acetylation performed by the liver.48 The efficacy 
of isoniazid and the incidence of the usual forms of isoniazid-induced toxicity are 
directly related to the intensity and duration of exposure to the drug. 15 Differing rates 
of acetylation account for the vast range observed in the half-life of isoniazid in 
individuals, resulting in different acetylator phenotypes.49 The enzyme responsible for 
this acetylation is N-acetyltransferase 2 (NAT2). The rate at which isoniazid is 
metabolised is not inducible and is inherited in a true Mendelian fashion so that 
individuals either display a slow (homozygous slow or mutant), intermediate 
(heterozygous) or rapid (homozygous rapid or wild type) phenotype.50•13 
N-acetylation is the primary metabolic route taken by certain drugs such as 
arylamines and hydrazines, including isoniazid. These drugs have been observed to 
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undergo N-acetylation at remarkably different rates in vitro as well as in vivo. 51 As 
certain other drugs belonging to this category have not displayed such a variance in 
metabolic rate, it was thought that there existed two types of N-acetyltransferase 
enzyme, both being responsible for N-acetylation, but only one of them showing such 
a distinct polymorphism. 
In the case of rapid and slow acetylators, it was hypothesised that either: 
• Each acetylator enzyme type possessed distinctly different physicochemical 
and kinetic properties, or 
• The two identical rate-limiting enzymes were present in different amounts due to 
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Figure 3.1a. The metabolism of isoniazid (adapted from Ellard and Gammon)49 
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The other drugs shown not to be influenced by acetylator status, are shown to be 
metabolised by a seemingly invariant enzyme termed monomorphic N-
acetyltransferase. 51 It has more recently been elucidated that this seemingly invariant 
enzyme is also polymorphically expressed.51 
The acetylation polymorphism of isoniazid is probably the most documented and 
well-described metabolic polymorphism in medicine. Price-Evans described it in 
1960.13 A study of 20 families, including 10 pairs of twins, was performed and the 
results showed conclusively that the phenomenon was evidence of a genetic 
polymorphism. Upon close examination of the twin data, it was concluded that the 
polymorphism was controlled by two segregating alleles. It was described as being 
bimodal, although Sunahara followed closely with the trimodal theory11 which has 
been supported by more recent publications.28•37•52 Today, the distribution is still 
considered to be trimodal, especially when dealing with genetic work, but the 
distinction between intermediate and rapid acetylators is still phenotypically 
tentative. 52 
Non-compartmental analysis has been utilised by researchers to calculate the 
pharmacokinetics of isoniazid.49 First order rate constants are calculated to describe 
the rate of acetylation in individuals (i.e. the rate of conversion of isoniazid to N-
acetylisoniazid). This rate constant has been proven to differ considerably between 
those classified as rapid acetylators and those classified as slow acetylators. In an 
experiment performed by Ellard and Gammon,49 it was shown that the rapid 
acetylator converted isoniazid to N-acetylisoniazid 3-4 times faster than the slow 
acetylator. It was then shown that this rate was comparable in each individual when 
acetylating monoacetylhydrazine, indicating that the enzyme responsible for 
converting isoniazid to N-acetylisoniazid was the same as that responsible for 
acetylating monoacetylhydrazine. 
Once isoniazid has been acetylated to form N-acetylisoniazid, it is biotransformed 
into isonicotinic acid and monoacetylhydrazine. lsonicotinic acid is then conjugated 
with glycine and the resulting product (isonicotinyl glycine) is excreted via the 
kidneys.49 
Studies have shown that isoniazid possesses the greatest early bactericidal activity 
of all known anti-tuberculosis agents. It was shown that the ratio of 300 mg isoniazid 
to the lowest dose producing a detectable EBA (18.75 mg), was observed to be 16.7 
By comparison, the ratio of a 600 mg dose of rifampicin to the lowest dose resulting 
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in a detectable EBA, was only 4.7 This indicates the effectiveness of this relatively 
inexpensive drug. 
Various techniques have been implemented to ascertain individual phenotypes. 
Drugs such as isoniazid,21 • 28• 53• 54· 55 dapsone27, caffeine,25• 26• 56 sulphamethazine50 
and sulphadimidine,23 known to be acetylated polymorphically, have been used. 
Plasma levels are favoured over urinary levels, because urine collection is less 
reliable than timed blood sampling.24 Markers such as isoniazid half-life, the level of 
isoniazid at three hours and the ratio of N-acetylisoniazid and isoniazid plasma levels 
at three hours28 have been some of the isoniazid markers used to classify patients as 
rapid, intermediate or slow acetylators. 
The influence of race or ethnicity of the individual on drug pharmacokinetics has 
been a topic of research for decades. Many studies have been performed to assess 
the differences between races on different drugs. The majority of recent studies 
have been performed comparing Asian (often Chinese) to Caucasian populations 
with limited publications comparing Caucasians with Africans (or African 
Americans).57 The coloured is unique to the Western Cape in terms of ethnicity. 
Nowhere in the world, besides South Africa, is there a comparable population. The 
incidence of tuberculosis is exceptionally high in the Western Cape, 107 historically 
deprived of good education and amongst whom poverty is rife. Many rely upon 
manual labour for their livelihood, such that becoming incapacitated seriously 
threatens their ability to sustain themselves and their dependants. 
In this report, the pharmacokinetics of isoniazid in patients admitted to Brewelskloof 
Hospital in Worcester in the Western Cape will be described. Using the 
pharmacokinetic data, it will be determined whether the distribution of acetylator 
status is indeed trimodal in this study population, as has been found in a prior study 
in the Western Cape.37 
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3.2. MATERIALS AND METHODS 
This study was passed by the ethics department at the University of Cape Town as well as 
the ethics committee set up at Brewelskloof TB hospital. It was carried out according to the 
study protocol for this project approved by the Medicines Control Council of South Africa and 
the Ethics Committee at the University of Cape Town. Each patient was required to sign an 
informed consent form prior to study recruitment (See Appendix I). Individual patient details 
are attached as Appendix V. 
Patient recruitment Patients admitted to Brewelskloof Hospital were recruited for the study 
the day prior to the study. Written, informed consent was obtained from each individual. 
Patients were recruited and sampled over an eight-month period. One hundred and fourteen 
patients successfully completed this study, 63 female and 51 male. All patients had been 
admitted to Brewelskloof Hospital two months prior to recruitment, and had been receiving 
standard therapy for 8 to 10 weeks. Concomitant therapy was not stopped for the purposes of 
this study. The standard therapy used at Brewelskloof TB Hospital consisted of rifampicin, 
isoniazid and pyrazinamide, with the addition of streptomycin and/or ethambutol if deemed 
necessary by the clinician responsible. 
Inclusion criteria: 
• 18 years old 
• Pulmonary tuberculosis: diagnosed by positive sputum or sputum culture 
• Patient with tuberculosis on treatment containing isoniazid 
Exclusion criteria: 
• critically ill 
• Contraindication to multiple blood sampling eg. mental confusion/poor venous 
access 
Study procedure The patients were fasted overnight from 24h00 until 1 OhOO the next 
morning.58 The zero hour blood sample was drawn within 30 minutes prior to medication 
administration. The medication was administered from 8h00, with 200 ml water. A light 
breakfast was allowed 2 hours after drug administration, providing time for adequate 
absorption. Following this, food and fluid intake was unrestricted. 
Patient sample collection Blood samples were collected from each patient over an eight 
hour period. Specific time points included 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0 and 8.0 hours 
after drug administration. Each time, venous blood was drawn from an indwelling cannula 
into gel lithium heparin-coated 4 ml glass tubes. These were stored on ice until being 
centrifuged, within 10 minutes, at 3 000 rpm for ten minutes. The plasma was then decanted 
into clean, labelled polypropylene tubes and stored on dry ice. Upon arrival back in Cape 
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Town, these were transferred to a -B0°e freezer. Following the 6-hour blood sampling, blood 
was drawn into EDT A tubes for genotypic analysis. 
Sample analysis Each sample was analysed for isoniazid and N-acetylisoniazid content by 
the method described in the previous section. The samples were taken out of -B0°e storage 
and allowed to thaw at room temperature. Following this, each tube was vortexed and spun 
down at 3 000 rpm for 5 minutes to remove any unwanted particulate matter, which would 
clog the solid phase extraction columns. Each sample was extracted and analysed according 
to the newly developed method discussed earlier. A new set of extraction columns was used 
for every twenty-five to thirty samples. 
Analyte recovery Each extraction set was monitored for consistent recovery by using spiked 
controls. Each extraction was accompanied by a 10 µg/ml spiked control of isoniazid and N-
acetylisoniazid to monitor that specific extraction. These spiked controls were also used to 
convert the HPLe peak area traces to concentration values. Standard curves were run with 
each set of analyses, to verify the assay linearity and conversion factors throughout sample 
analysis. 
Patient profiles A pharmacokinetic profile of isoniazid and N-acetylisoniazid was 
constructed for each patient using GraphPad Prism (v 2.01, 1996). All subsequent graphs 
were plotted using this software package. 
Pharmacokinetic data The software package WinNonlin Standard Edition (v 1.5) was used 
to calculate the non-compartmental pharmacokinetic parameters for each patient. Parameters 
calculated included: 
1. Cmax - the maximum concentration reached (achieved via inspection of the 
pharmacokinetic time curve) 
2. Tmax - the time at which this observed concentration is reached (achieved via inspection 
of the pharmacokinetic time curve) 
3. Thalf - the apparent terminal half-life of the analyte (NOTE: the WinNonlin algorithm was 
used for the decision of the number of points to include in the calculation of half-life.) 
The terminal half life of a drug is estimated when estimating Az. "'z may be defined as the first 
order rate constant associated with the terminal (log-linear) portion of the curve. It is 
estimated by plotting a linear regression of time vs. natural log concentration . Lambda z = -1 
* slope of regression. The estimated lambda z value is always associated with a coefficient of 
determination (R2). which should tend to 1. 
The terminal half life is calculated using the equation: t112 = In (2) / A.z 
The goodness of fit calculated for this terminal elimination phase curve is given as Rsq. 
4. AUCall - the total area under the curve from the time of dosing to the time of the last 
observation (referred to as AUCT for the purposes of this work). 
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AUClast - the total area under the curve from the time of dosing to the time of the last 
measurable concentration. This differs from AUCall because it excludes the use of any 
points, which produced concentrations of zero. 
Two methods are available to calculate area under the curve using this package. When the 
Linear/Log Trapezoidal calculation method is implemented, the Linear Trapezoidal rule is 
used up to Cmax. The Logarithmic Trapezoidal Rule is used after Cmax has been reached. 
If there are any concentrations of zero after Cmax, the linear trapezoidal rule is used for 
intervals that contain the zero concentration. If Cmax is not unique, then the first occurrence 
of Cmax and its corresponding Cmax is used. 
12 
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5. AUCINF - the area under the curve from the time of dosing extrapolated to infinity, if the 
last measured concentration was above zero. 
This parameter is calculated using the equation: AUCINF = AUClast + Clast / Az 
Rate constant calculation was performed using the equation: In C1 = In C0 - kt 
Natural logarithms of each point subsequent to that of Cmax, up to 8 hours, were taken. From 
the above equation, the elimination rate constant is the slope of the regression line multiplied 
by -1 . These were then compared to the lambda z values obtained using WinNonlin, 
calculating the half-life. This was done because it provided a good estimation of the validity of 
the use of program-selected lambda z values to calculate half-life. WinNonlin calculates 
lambda z in the same manner as the rate constant is calculated manually, deciding upon the 
validity of including each point. 
Statistical Analysis was performed using non-parametric statistics on GraphPad Prism (v. 
2.01 ). Correlations were assessed using the Spearman r test, and statistical differences 
between groups using the Mann Whitney test. 
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3.3. RESULTS OF SAMPLE ANALYSIS 
The study began with the analysis of each plasma sample from each patient. These 
were analysed according to the method described in Chapter 2, and pharmacokinetic 
curves for isoniazid and N-acetylisoniazid were constructed. These are shown in 
Appendix II (Figures Ila - lip). 
The entire sampling population was assayed using HPLC, in sets to facilitate 
optimum column usage, and the composite profiles obtained for each drug in each 
set are shown in figures 3.3.1 a and b. 
Controls were used throughout sample analysis in order to ensure assay integrity. 
The results of each of the sets of controls are presented in figure 3.3.2. Care was 
taken to minimise the error bars during analysis. 
The data obtained using the previously discussed assay is represented in the above 
set of graphs. Each graph represents an individual in the study, showing the 
pharmacokinetic profile of isoniazid and N-acetylisoniazid. It is evident from these 
graphs that there is indeed a wide range of acetylation capacity within this study 
population. A previous study performed by Peloquin and Jaresko et a/.59 showed 
ranges using a 250 mg dose of isoniazid, expected for the major pharmacokinetic 
parameters discussed here. 
Table 3.3.1. Observed ranges of three major pharmacokinetic parameters59 
i:Paiameter '·· . · '. .-.~ ... "'.' ' ·· · ·. · R;foge · ' · : ... _. '"'.tf¥j 




2.17 - 5.11 
0.50 - 3.00 
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Although the majority of subjects display adequate levels with regard to therapeutic 
ranges, the variability is distinct, with eight subjects not reaching the lower limit of the 
therapeutic range (3 µg/ml). Certain Cmax values for isoniazid show that the levels 
obtained for a number of individuals are elevated, many reaching above 10µg/ml. 
The metabolite levels range from far below that of the parent drug to well above the 
maximum concentration reached by isoniazid. 
Rapid absorption of the drug is evident, most concentrations peaking before two 
hours. It is also clear that the time period over which each individual was studied 
was not long enough to provide an accurate estimation of terminal half-life of 
isoniazid as certain individuals (including 81, 90, 92, 93 and 102) did not have time to 
achieve very low concentrations of isoniazid. 
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Figure 3.3.1a. lsoniazid profiles of all patients in composite form. The graphs are displayed in 
the sets in which they were analysed. In certain cases, it is evident that there are distinct 
differences in the profiles of isoniazid between individuals, even when they are receiving 
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N-acetylisoniazid Profiles N-acetylisoniazid Profiles 
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Figure 3.3.1 b. N-acetylisoniazid profiles of all patients in composite form. Again , the graphs 
are arranged in sets according to their analysis. The separation of individuals into phenotypic 
acetylator groups is again fairly evident, since this metabolite is the product of the phenotypic 
polymorphism. 
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Figure 3.3.2. The spiked controls ran during each set of analysis are represented here. The 
ratio of each set was used to convert the peak areas in that set into concentration . 
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As can be seen from the graphs, the controls remained consistent with their spiked 
concentrations. The standard errors of the mean were minimal. The conversion 
factors calculated from that specific set of controls were used to calculate the 
apparent concentrations of the controls following analysis, and subsequently, those 
patients' samples analysed in that set. 
All the samples obtained from each subject enrolled in the study were analysed 
successfully. The controls produced excellent estimations of concentration, with 
minimum variation and error. The concentration data was analysed and used to 
assign acetylation status to each individual. 
3.4. ANALYSIS OF RESULTS 
The analysis of plasma samples was followed by interpretation of these values. In 
order to be able to do this, three areas had to be dealt with. They were: 
i. Frequency distributions: Determining the optimal method of phenotypic 
classification. 
ii. Pharmacokinetic Trimodality: Determination and analysis of pharmacokinetic 
parameters according to the phenotypic 
iii. Rate constant Evaluation: 
classifications made using frequency 
distributions. 
Determination of the elimination rate constant of 
isoniazid and the rate of formation of N-
acetylisoniazid. 
3.4.1. Frequency Distributions: Phenotype Criteria 
Various means have been used to ascertain the acetylator phenotype in humans. 
Using isoniazid, half-lives have been assessed, as well as the plasma level at three 
hours.28 The ratio of AclNH:INH at three hours post dose was examined first. (See 
figure 3.4.1 a.) 
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Frequency Distribution of Log (AclNH: INH) 
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Figure 3.4.1a. Frequency Distribution of the logarithm of the ratio of isoniazid to N-
acetylisoniazid at three hours. 
The above distribution suggests that: 
1. the distribution is trimodal , 
2. the separation of rapid and intermediate acetylators is not discrete, whilst that of 
slow and intermediate is, and 
3. the antimode separating slow and intermediate acetylators is discrete and may be 
estimated as being -0.4. The antimode between rapid and intermediate 
acetylators is not as discrete, but may be estimated as being 0.2. 
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Figure 3.4.1 b. The distribution of isoniazid concentration at three hours post dose. 
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A trimodal distribution is not as easily seen using this marker. This marker fails to 
independently provide an adequate means of determining acetylator phenotype. The 
distribution of isoniazid concentration at three hours post dose illustrates a bimodal 
distribution, the antimode being under 6 µg/ml. 
Frequency Distribution 
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Figure 3.4.1 c. Distribution of acetylation using the half-life of isoniazid as a marker. 
The distinction between the different classes of acetylators is not easily seen when 
using the half-life of isoniazid as a phenotypic marker for acetylator status (figure 
3.4.1c.). The slower the acetylator, the longer the half-life of isoniazid should be. The 
terminal elimination phase was not adequately represented in some patients as 
sampling only occurred up to eight hours post drug administration. Possibly, the 
sampling period could have been extended in order to provide better half-life 
estimation, remembering that the determination of half-life requires at least three 
points on the terminal elimination curve. 
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Figure 3.4.1 d. Distribution of acetylator status using the calculated AUCT values to 
determine phenotype. 
An apparent trimodal distribution is evident in this figure, pointing towards the 
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Figure 3.4.1e. The mean phenotypic split of log (N-acetylisoniazid: isoniazid) at three hours. 
The distribution of Log (AclNH:INH) at three hours gave the best estimation of 
trimodal distribution, and the criteria for phenotypic classification. Performing non-
parametric Mann Whitney statistical tests on these three subgroups, rapid, 
intermediate and slow, each group was determined to be highly significantly 
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different at a 95% confidence interval, using a two-tailed test (p <0.0001 ). This 
classification criterion divided the population into 36 rapid acetylators, 54 
intermediate acetylators and 24 slow acetylators. 
Table 3.4.1 i. Correlation between the use of different phenotypic markers for 
determining acetylator status (using a two-tailed Spearman Correlation at 95% Cl) 
•,.,-J'~::- . 1-1->-: · r-.1, Spearmanrvalue Pvalue 
Log (AclNH:INH) at 3 hours vs. -0.2841 0.0022 
lsoniazid at 3 hours 
Log (AclNH:INH) at 3 hours vs. -0.1043 0.2694 
lsonlazld half-life 
lsonlazld half-life vs. -0.2209 0.0182 
lsonlazid at 3 hours 
Thus, the method chosen for phenotyping and classifying individuals into acetylator 
status subgroups, was the log (AclNH:INH) value at three hours. 
Table 3.4.1 ii. The degree of difference between acetylation in the three phenotypes 
(± SEM). 





Slow Acetylators Intermediate Rapid Acetylators 
Acetylators 
0.2451 ± 1.118 ± 0.2703 2.280 ± 0.7773 
0.06404 
4.561 times 9.302 times 
0.2192 times 2.039 times 
0.1075 times 0.4904 times 
All comparisons are highly significantly different, at a 95% Cl, using a two-tailed 
Mann Whitney test. 
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3.4.2. Pharmacokinetic Trimodality 
The resulting individual values obtained for Cmax, Tmax, Thalf, AUCT and AUCINF 
were analysed by grouping individuals according to the criteria decided upon using 
the frequency distribution of Log (AclNH:INH). All statistical testing was performed 
using two-tailed nonparametric Mann Whitney tests, at a 95% Cl. (* indicates the 
degree of statistical significance.) 
Rapid vs. Slow 
lntermed vs. Slow 
lntermed vs. Rapid 
Sig. Difference? 
Yes, p < 0.0001 
Yes; p = 0 0009 
No· p = 0.1329 
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Slow Intermediate Fast 
Acetylator Phenotype 
Figure 3.4.2a. Trimodal comparison of maximum plasma concentration reached (± SD). 
The non-discrete separation between the intermediate and rapid acetylators, as 
displayed in the frequency distribution of concentration (figure 3.4.1 b ), is evident 
here. 
Eight subjects were found to display maximum concentrations of isoniazid, below the 
suggested therapeutic range (i.e. below 3 µg/ml). Five of these subjects were rapid 
acetylators and 3 were intermediate acetylators. If one could assume that the 
acetylator status of the individual was the only factor affecting the Cmax value, then 
the relative risk of rapid acetylators to fall below the therapeutic range, compared to 
intermediate acetylators would be 2.500 compared to intermediate acetylators. It is 
not possible to compare this incidence to that of slow acetylators, as there were no 
subjects, regarded as slow acetylators, who failed to achieve at least minimum 
therapeutic levels. 
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· Sig. Difference? 
Rapid vs. Slow 
lntermed vs. Slow 
lntermed vs. Rapid 
Yes; p = 0.0204 
No; p = 0.2362 
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Slow Intermediate Fast 
Ace.tylator Phenotype 
Figure 3.4.2b. Analysis of the time of maximum plasma concentration (± SD). 
The only groups displaying any significant difference, were the rapid and the slow 
acetylators. There was a large degree of variation within each group, demonstrated 
by the large standard deviation. 
,, Sig. Difference? 
Rapid vs. Slow 
lntermed vs. Slow 
lntermed vs. Rapid 
Yes; p = 0.0394 
Yes; p = 0.0203 
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Figure 3.4.2c. Trimodal comparison of the mean half-lives (± SD) displayed by each 
acetylator group. 
This finding is evidence of the non-discrete separation of the intermediate and rapid 
acetylators. It shows that these two groups are difficult to distinguish between. The 
separation of slow acetylators into a discrete group is apparent. 
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Figure 3.4.2d. A comparison of the differences between the acetylator groups in terms of 
total area under the curve(± SD) (i.e. to the last observation). 
It is clear that acetylator status affects this pharmacokinetic parameter quite 
considerably, reducing the exposure of rapid acetylators to isoniazid by half. 
·, · Sig. Difference? 
Rapid vs. Slow Yes; p < 0.0001 
lntermed vs. Slow Yes, p < 0.0001 
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Figure 3.4.2e. Statistical comparison of the acetylator phenotypes in terms of the area under 
the curve, extrapolated to infinity (± SD). 
The enzymatic polymorphism has a distinct effect on the values generated for this 
parameter, as it had with the total area under the curve. 




















Figure 3.4.2f. The correlation between the use of Log (AclNH:INH) and the use of AUCT 
(AclNH):AUCT (INH) as markers for acetylator status. 
This figure illustrates the significant correlation between the use of the [AclNH:INH] 
ratio at 3 hours as a marker for acetylator status; and the use of the ratio of [AUCT 
for N-acetylisoniazid : AUCT for isoniazid], emphasising the effect of acetylator status 
on the area under the curve. Statistically, the correlation is significant, producing a 
Spearman r-value of 0.9367 (p<0.0001 ). By comparing this figure with figure 3.4.1 d 
(Page 57), acetylator status phenotype may be determined by either using the ratio 
of a single point on each curve, or by the ratio of the areas under both curves, the 
curves being that of metabolite and drug. 
Table 3.4.2i. The mean observed pharmacokinetics of isoniazid for each acetylator 
phenotype (±SEM) 
Cmax (µg/ml) 7 .177* ± 1.867 5.589 ± 2.406 4.811 ± 1.847 
Tmax (h) 1.700 ± 0.866 1 .454 ± 0. 7664 1 .200 ± 0.5450 
Thalf (h) 4.087* ± 1.064 3.564 ± 1.027 3.537 ± 1.061 
AUCT (µg.h/ml) 32.39* ± 6.531 21.25* ± 7.756 16.04* ± 5.088 
AUCINF (µg.h/ml) 45.00* ± 7.363 27 .05* ± 9.498 21.08* ± 7.059 
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The pharmacokinetic parameter means do indicate a marked difference between all 
three phenotypes, but the trimodal theory still remains tentative in certain areas, such 
as Cmax and Thalf. It is difficult to ascertain the extent to which these figures agree 
previously determined values, as little pharmacokinetic modelling has been 
performed using three acetylator groups. Compared to the values from Table 3.3.1 
(page 49) the figures above seem raised, although the first study did use a 250 mg 
dose instead of 300 mg. 
Chapter Three: Pharmacokinelics and Acetylator Status 64 
3.4.3. Rate Constant Evaluation 
In order to obtain an overall view of the interindividual difference in isoniazid plasma 
levels, composite graphs of each acetylator phenotype were plotted. All the 
calculated rate constants may be found in Appendix IV. 
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Figure 3.4.3a. Composite plot of the phenotypically slow acetylators. The solid lines indicate 
the therapeutic range of isoniazid. 
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Figure 3.4.3b. Composite plot of the phenotypically intermediate acetylators. The solid lines 
indicate the therapeutic range of isoniazid. 
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Rapid Acetylators 
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Figure 3.4.3c. Composite plot of the phenotypically rapid acetylators. The solid lines indicate 
the therapeutic range of isoniazid. 
There is the marked amount of variation within each phenotype, and not just between 
the groups. 
A. The Observed Rate of Elimination of /soniazid 
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Figure 3.4.3d. A graphical representation of the mean pharmacokinetic profiles of isoniazid in 
each acetylator phenotype. 
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The profiles of each individual in a specific phenotypic group were averaged and 
mean profiles compiled . Each point is associated with a standard error. It is evident 
that the mean profiles are very different, and this supports the calculation of 
individual rate constants for isoniazid. 
Elimination Rate Constants Elimination Rate Constants 
0.3~--------------, 
0.2426 ±0.011 16 
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Figure 3.4.3e. The calculation and trimodal split of mean elimination rate constants of 
isoniazid phenotype subgroups. 
Natural logarithms were taken of each mean concentration point, and linear 
regression was performed in order to calculate the mean rate constant. The 
coefficients of determination for the resulting regression lines were 0.9890, 0.9852 
and 0.9403 for slow, intermediate and rapid acetylators respectively. 
Using a two-tailed non-parametric Mann Whitney test, significant difference was 
found in slow vs. rapid, and slow vs. intermediate acetylators, but not between 
intermediate and rapid acetylators, thus reflecting the previous findings using 
isoniazid half-life. 
From the data above, the alleles coding for acetylator status appear to be co-
dominant. By averaging the mean k values for slow and rapid acetylators, it is 
possible to estimate the mean k value for intermediate acetylators within 6% of the 
true mean (0.2171 vs. 0.2299). 
This also served to indicate the validity of the choice of lambda z by WinNonlin for 
use in calculating the half life of isoniazid. By specifically selecting the points used to 
calculate the rate constant, calculating the rate constant and comparing it with the 
lambda z value estimated by WinNonlin, the non-parametric Spearman r correlation 
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B. The Observed Rate of Formation of N-acetylisoniazid 
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Figure 3.4.3f. The mean pharmacokinetic profiles of N-acetylisoniazid phenotypically split into 
a trimodal distribution. 
These profiles were then used to calculate the apparent rate of formation of N-
acetylisoniazid, by plotting the regression of all the points leading to the Cmax. 
Individual rates of formation were calculated, and then the mean determined as a 
phenotypic characteristic, in order to judge whether the groups are significantly 
different in terms of rate constants, governed by the enzyme, N-acetyltransferase. 
0.0 
Rate of Formation 
N-acetylisoniazit 
-
Trimodal Formation Rate 
Constants 
4+----+----+----i-----t-
3 ____ __ , _____ _ , _____ _ Slow , SD 
Intermediate , S D 
~ - -0.5 w ... 
u, · ... 
:z:: 




............... -0 .7530 I 0.07027 
-0.9436 I 0.07872 





-1 ' ' - --- _ _ i _ _ ___ - . --- - - -
-1.s~-----------~ 
Slow iltermediate Fast 
-2---~---------+ 
0.0 0.5 1.0 1.5 2 .0 
AcetylalDr phenotype lime (hours) 
Figure 3.4.3g. The calculation of the rates of formation of N-acetylisoniazid in each 
phenotype. 
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R2 values for each regression line were 0.9715, 0.9443 and 0.9329 for slow, 
intermediate and rapid acetylators respectively. The mean rate of formation for each 
group is highly significantly different (***) from those of the other groups, using the 
two-tailed Mann Whitney test at a 95% Cl. 
The correlation between the rate of disappearance of isoniazid and the rate of 
formation of N-acetylisoniazid was found to be insignificant, using the Spearman 
correlation (non-parametric) at a 95% Cl, with the Spearman r = 0.01944, and the P 
value of 0.8373. 
3.5. DISCUSSION AND CONCLUSIONS 
The distribution of acetylator status in most populations has long been assumed to 
be bimodal.17• 19• 20• 20• 22• 31 • 33• 34• 35• 60• 61 Even with the advent of genotypic methods to 
assess the genotype coding for acetylator status there was still this assumption, 
although there was evidence of a separation between heterozygous fast and 
homozygous fast acetylators.32• 50 
However, over the years, there has been an accumulation of evidence to show that 
the elimination of isoniazid is trimodally distributed.11 • 28• 52• 37• 62 This study has 
confirmed this, demonstrating significant differences between the three acetylator 
phenotypes. 
The acetylation polymorphism is overtly evident in the individual patient profiles 
(Appendix II). Comparing the graphs of parent drug to metabolite provides insight into 
the apparent phenotype of the subject. The implementation of markers to gauge 
acetylation rates proved that the only reliable markers were 
(a) the logarithm of the ratio of N-acetylisoniazid to isoniazid at three hours 
(b) and the logarithm of the ratio of the areas under the curve for N-
acetylisoniazid to isoniazid.{See figures 3.4.1a-d). 
Thus the determination of acetylator status via ratio analysis is the most definitive, 
the ratio analyses correlating highly (Figure 3.4.2f.). 
Numerous other publications have used the 3-hour level indicator to assess 
acetylator status, producing very distinct results. The distribution in this study was 
trimodal, with the antimodes clearly visible at -0.4 and 0.2, using a standard dosage 
of 300 mg isoniazid (Figure 3.4.1a.). These antimodes also apply to the use of the 
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AUCT ratios (Figure 3.4.1 d.). Phenotypically assigning each subject an acetylator 
phenotype using the 3-hour level model worked well and provided an excellent 
starting point for pharmacokinetic analysis. Ease and practicality of sampling 
influenced selection of this marker. 
Statistical analysis of the log (AclNH:INH) ratios for each group did show significant 
differences between all three groups, at a 95% Cl (figure 3.4.1 e ). Other indicators 
used (Cmax and isoniazid half-life) did not provide such a definite phenotypic 
distinction, but the trend did tend towards trimodality, with notable separation of the 
slow phenotype from the remaining subjects. The separation between intermediate 
and rapid acetylators is not as discrete, regardless of the marker implemented, 
although the use of the area under the curve does provide better insight into the 
acetylator status of the population than most other parameters. 
In previous publications, the difference in the rate of acetylation has always been 
between rapid and slow acetylators, and ranges from a 4- to 6-fold difference. 14· 15• 49 
Using the ratio of N-acetylisoniazid to isoniazid plasma levels at three hours, this 
trimodal distribution proposes that rapid acetylator display acetylation rates over nine 
times that of slow acetylators, and double that of intermediate acetylators (See table 
3.4.1 ii). Bearing this in mind, it is evident why there should be such a difference 
between pharmacokinetic parameters for the three groups. 
The absence of absolute correlation between the three indicators used suggests that 
they are not interchangeable {Table 3.4.1 i). The best correlation was between the 
ratio of metabolite to drug at 3 hours and the plasma level of isoniazid at three hours. 
This was expected, as the two markers are related, both involving the use of the 
concentration of isoniazid at three hours. The correlation between isoniazid half-life 
and isoniazid at three hours suggests that these markers are still useful. It may be 
argued that the correlation between half-life and the ratio was insignificant due to the 
error in half-life estimation because of the reduced sampling period. Sampling up to 
eight hours provides useful information for most pharmacokinetic parameters, but the 
best estimation of half-life would have to include later points. The elimination rate 
constants concur with this finding. 
The range of maximum concentrations reached (Cmax) is broad even within various 
acetylator groups, shown by the large standard deviations (figure 3.4.2a). It is 
evident that the study design allowed for a good estimation of Cmax, with numerous 
sampling points within the first three hours following drug administration. Acetylator 
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status definitely affects Cmax, showing statistical significance between rapid vs. slow 
and intermediate vs. slow, but again alludes to the fact that the distribution is bimodal 
in terms of maximum concentration reached, by failing to draw significance between 
rapid and intermediate acetylator status. 
Penetration of isoniazid into lesions and sites of infection is critical to its activity 
during drug therapy. The aim of drug therapy would be to intensify drug exposure, 
maximising the maximal concentration reached, such that distribution around the 
body is optimal and allows maximal penetration into lesions and cysts.29· 63 
Even though evidence has established that acetylator status does not affect outcome 
during the daily treatment,55 according to the estimated therapeutic range of isoniazid 
(3-6 µg/ml 64), 8 out of 114 subjects failed to achieve this plasma concentration. Of 
these, 5 were rapid acetylators, translating into a relative risk of 2.5 that rapid 
acetylator will be sub-therapeutic compared to intermediate acetylators. This means 
that according to the information obtained from this population sampling, rapid 
acetylators are 2.5 times more likely not to achieve a minimum concentration of 3 
µg/ml. Whether this may be translated into a compromised outcome, depends on 
further kinetic studies, relating these concentrations to clinical outcomes. There were 
no instances where a slow acetylator peaked below 3 µg/ml. 
The determination of the time at which the maximum plasma concentration was 
reached {Tmax) was performed by inspection of each pharmacokinetic profile. The 
resulting values were consistent with literature values, 15• 47 the means for rapid, 
intermediate and slow being 1.2 h, 1.45 h and 1. 7 h respectively (Figure 3.4.2b ). 
There was a significant difference (p = 0.0204) between the Tmax values of the rapid 
and the slow acetylator groups. This factor is strongly confounded by absorption, a 
factor inherently variable and independent of acetylator status. 
The distribution of half-life is evidently bimodal in this population, as has been found 
previously.59 Although sampling interval was short, the estimates of goodness of fit 
(Rsq) during the determination of half-life are excellent (Appendix Ill) and in previous 
studies sampling was extended to 36 hours with still no evidence of trimodality.59 The 
frequency distribution of half-life (figure 3.4.2c.) also did not discriminate between 
rapid and intermediate acetylators. It was clear though, that there is a discrete 
isolation of the slow acetylators, each t-test showing significant difference. 
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lsoniazid targets the mycobacterial cell wall.65 Thus, optimisation of drug therapy by 
maximising the amount of time the drug level exceeds the minimum inhibitory 
concentration (MIC) follows.47 In terms of pharmacokinetics, the most important 
indicator of drug efficacy should be the total area under the curve (AUCT), with 
special reference to the time that drug concentration exceeds the MIC.47 In rapid 
acetylators, this may become a problem if the patient is exceptionally fast and does 
not achieve adequate absorption. Significant differences exist between all three of 
the acetylator subgroups, implying that this parameter is largely influenced by 
acetylator status (Figure 3.4.2d). The fact that the slow acetylators showed an AUCT 
double that of rapid acetylators means that the exposure of the mycobacteria to 
isoniazid is halved in rapid acetylators. In the absence of regular dosing, 5% of rapid 
acetylators are known to fail in treatment or at least fair considerably worse than 
slower acetylators.66 
The acetylator phenotype is of considerable significance during once-weekly therapy, 
but it may also be of significance during twice weekly treatment, when the companion 
drug is relatively weak.55 This is emphasised when extrapolating the area under the 
curve to infinity (AUCINF). The trend between acetylators is the same here, the rapid 
acetylators (21.08 µg.h/ml ± 7.059) still receiving less than half the exposure of slow 
acetylators (45.00 µg.h/ml ± 7.363) to isoniazid (figure 3.4.2e.). Each group was 
significantly different (p <0.0001 ), implying that there is a significant difference in drug 
exposure experienced by each of the phenotypes. 
Taking this observation into account, the use of total area under the curve for 
determining acetylator phenotype is a viable option, and this, including significant 
correlation between the two factors , has been shown incontrovertibly by figure 3.4.2f. 
The mirroring of the scatter of Log (AclNH:INH) at three hours is obvious. 
The significant reduction of the AUC in rapid acetylators would surely affect drug 
exposure during once-weekly intermittent therapy, where the action of isoniazid is 
critically complementary to rifampicin, bactericidal activity and resistance 
prevention. 63 
The elimination rate constant must be clarified in terms of it being the portion of the 
pharmacokinetic profiles (2.5 to 6 hours) indicating the elimination phase, specific to 
each patient profile, related to the disappearance of isoniazid from the blood plasma. 
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The disappearance of isoniazid in this aspect was observed to be bimodal, as 
expected after viewing the results from the half-life calculations. Slow acetylators 
were discretely separated from intermediate and rapid acetylators. Slow, 
intermediate and rapid acetylators were statistically significantly different from each 
other, calculating linear regressions for each group. Thus the individual rate 
constants in each group did produce significant difference for acetylator phenotype 
(See figures 3.4.3d. and 3.4.3e.). 
In terms of gene penetrance, it is evident that the alleles coding for slow or rapid 
acetylation are codominant. It is possible to estimate (within 6%; 0.2171 vs. 0.2299) 
the elimination rate constant for the intermediate acetylators by averaging those 
obtained for the rapid and slow groups. 
N-acetylisoniazid may be the major metabolite of isoniazid, but it is not the only 
product. lsoniazid is also broken down into a-oxoacids, namely pyruvic hydrazone, a-
ketoglutaric hydrazone and direct hydrolysis to isonicotinic acid and hydrazine (See 
figure 3.1 a).49 Thus this terminal rate constant cannot be assumed to reflect the 
absolute activity of N-acetyltransferase 2, but it may be indicative of it, depending 
upon the nature of hydrazone formation and the rate of renal excretion of unchanged 
isoniazid. Taking all these confounding factors into consideration, the rate of 
disappearance of isoniazid in an individual would not be an ideal method of 
determining the acetylator phenotype of that individual. 
The only means of forming N-acetylisoniazid is via the enzymatic action of N-
acetyltransferase 2. So it would be logical to deduce that the rate of formation of N-
acetylisoniazid would correlate more directly with the activity of the enzyme. 
Allocating individuals acetylator status determined by the log (AclNH:INH) ratio at 
three hours, and subsequently analysing the differences seen in the rates of 
metabolite formation, shows a distinct trimodality. The mean rates of formation are 
highly significantly different from each other (p < 0.0001) (figures 3.4.3f. and 3.4.3g.). 
The correlation (figure 3.4.3h) between the rate of disappearance of isoniazid and 
the rate of formation of N-acetylisoniazid was found to be insignificant. An increased 
rate of isoniazid disappearance did not necessarily translate into a high rate of N-
acetylisoniazid formation. Providing a more complete graph of the metabolite in the 
early phase following drug administration might strengthen the rate calculation. 
Confounding factors may be the renal elimination of unchanged isoniazid, owing to 
unregulated fluid intake, and the hydrolysis of isoniazid into other products. 
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Thus the conclusions drawn from this investigation are that acetylator status is 
trimodal in this population. This is best determined using a frequency distribution of 
log (AclNH:INH) at three hours (see Chapter 4 for validation of this) for ease, and 
substantiated by the distribution of the ratio of AUCT AclNH:AUCT INH. 
3.5. FINAL CONCLUSIONS 
This population has been shown to be demonstrative of a previous report regarding 
the trimodality of isoniazid.37 The logarithm of (AclNH:INH) at three hours has been 
determined to be an accurate marker for phenotype determination, displaying a 
trimodal distribution. This was substantiated by using the logarithm of 
(AUCT AclNH:AUCT1NH), both markers correlating well with each other. Trimodal 
analysis the resulting pharmacokinetics revealed significant separation of the slow 
acetylators from the intermediate and rapid acetylators in all cases. Cmax and half-
life was bimodally distributed, failing to draw significance between the intermediate 
and the rapid acetylators. The area under the curve was observed to be trimodal, 
significant statistical difference existing between all three acetylator phenotypes. Of 
concern is the significant reduction in AUC displayed by rapid acetylators, as well as 
the elevated relative risk of rapid acetylators to achieve sub-therapeutic levels of 
isoniazid. In other drugs, this would not always attract heightened concern because 
many metabolites are still active against the targeted organism. The fact that the 
metabolites of isoniazid are totally inactive makes this reduction therapeutically 
significant. 
Examination of the elimination rate constants for isoniazid confirm earlier 
suggestions 11 •67 that the alleles are codominant, the predicted mean rate constant for 
the intermediate group being within 7% of the calculated mean. 
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CHAPTER FOUR 
THE G.ENETICS OF N-ACETYL TRANSFERASE 2 
4.1. INTRODUCTION 
74 
N-acetylation may be defined as the conjugation, catalysed by acetyl CoA-dependent 
arylamine acetyltransferase (NAT) enzymes, of primary amino and hydroxylamino 
groups with acetate. The is a certain amount of toxicity connected to this group of 
enzymes, due to the fact that they catalyse the conjugation of many xenobiotics and 
procarcinogens.68 Shortly after the demonstration of the activity of isoniazid against 
tuberculosis in humans 1, it was observed that there existed a distinct polymorphism 
in the metabolism of this drug. 10· 69· 70 
Prior to the advent of molecular genetics, family studies were undertaken to 
understand the nature of the polymorphism. 13 It was noted that a slow acetylator 
seemed to possess autosomal homozygous recessive alleles. This confirmed the 
earlier work of Knight and Selin et aJ.7° Furthermore, it was concluded that there 
existed a dosage effect, whereby the heterozygous inactivators displayed a 
considerably higher plasma isoniazid concentration than homozygous dominant 
individuals. From the above facts, it was presumed that "the allele controlling the 
dominant character gives rise to a process, which speeds the inactivation of 
isoniazid"13 and that the process was most likely enzyme-mediated. Subsequently, 
Jenne71 published the results of a partial purification of isoniazid transacetylase from 
human liver. He was unable to distinguish the heterozygotes in terms of in vitro 
analysis, and the lack of correlation between in vitro and in vivo results was 
explained by other physiological processes contributing to drug disappearance, such 
as hydrazone formation or continuous diffusion. But a broad range of acetylation 
activity was observed, most likely to be dependent upon the amount of enzyme 
present, and the activity was definitely distributed bimodally,72 if not trimodally,11 • 73 
with slow acetylators exhibiting significantly less activity than their rapid 
counterparts. 71 
Later, the impairments (or recessive traits) were pinpointed to a reduction in the rate 
of N-acetylation by a cytosolic CoASA:arylamine N-acetyltransferase enzyme in a 
two-step reaction involving the transfer of acetate from acetyl CoA to primary 
aromatic amino and hydrazino functional groups.74 
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N-acetyltransferase work achieved new heights when two distinct NAT genes -
NA T1 and NA T2 - were cloned and the NA T2 gene locus was determined to be the 
site of the human isoniazid acetylation polymorphism.75 Alleleic variants are 
translated into different gene products resulting in differences in individuals with 
respect to the metabolism of xenobiotics.68 The resulting protein isoforms exhibit 
overlapping degrees of selectivity, resulting in a large degree of versatility in different 
individuals.68 Because this variation occurs within a single gene locus, it is termed 
monogenic and results in a range of acetylation activities from extensive to poor.68 N-
acetyltransferases catalyse a 2-step reaction involving the dissociation of the acetate 
group from Co-enzyme A, and the conjugation of this group to the primary amino or 
hydrazine functional group.68 The use of molecular genetics was to shed more light 
on the issue surrounding the activity and structural heterogeneity of the acetylation 
phenomenon. 
The allelic nature of NA T2 was subsequently determined, and a number of allelic 
variants of NAT2 have been identified; several of these alleles giving rise to the well-
studied isoniazid acetylation polymorphism .Andres and Vogel et al. were the first to 
determine the amino acid composition of 6 tryptic peptides obtained from 
homogenised liver NAT from rapid acetylator rabbits, electrophoretically separated 
and sequenced.76 These peptides made the construction of oligonucleotide screening 
probes possible. Using such probes, NAT cDNAs were isolated from Japanese 
subjects, obtained from libraries made with mRNA from two liver samples.77 The NAT 
genes were identified at three distinct loci and named NA T1 (supposedly 
monomorphic NA 1), NAT2 and NATP (a pseudogene). The sizes of these genes 
were determined by restriction enzyme digestion with EcoR1, yielding fragments of 
1.3, 1.9 and 4.7 kb respectively.75 
The NA T2 gene contains an open reading frame of 870 bp, encoding a protein of 
33.5 kDa. The coding exon for this gene is intronless. The coding region of NA T2 
presents with 87% nucleotide homology to NA T1, translating into 80% amino acid 
homology. 77·75 
In this study, the nomenclature of Hickman and Sim50 has been adopted. By 
convention the wild type allele (FF) is considered to have no (known) mutations 
affecting the activity of the translated protein. Functional work thus far has suggested 
that mutant alleles are the result of a combination of between one and three 
nucleotide substitutions, occurring at positions 191,282,341,481,590,803 and 857-:-
Position 341 is the only mutation undetected by restriction enzyme digestion. It is 
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known that only mutations at positions 191, 341, 590 and 857 give rise to amino acid 
changes that in turn result in defective protein function.68 The mutations are specific 
in the effect they have on the activity of the protein . It was found that nucleotide 
substitutions at positions 191 and 590 produced proteins with reduced stability and 
catalytic activity. Mutations at positions 341 alone, or coupled with positions 481, 
803 or both, produced enzymes with significantly reduced catalytic activity only.78 
In terms of determining NAT2 genotype, the mutation at nucleotide 481 (C > T) 
results in the loss of the Kpnl restriction enzyme cutting site and has been named S1 
(or formally NAT2*5A, 58). The S1 allele has been split up into three different alleles, 
namely S 1 a, S 1 b and S 1 c. The only S 1 allele not picked up by the loss of the Kpnl 
site is S1c. It is evident via the addition of a Ddel cutting site. Additional mutations 
are also associated with the S1 allele, namely 341 (T > C) base change, resulting in 
a substitution of isoleucine114 for threonine, and the silent 803 (A> G) base change, 
but it is the loss of the Kpnl cutting site, which has been used to differentiate S1 from 
other alleles. This mutation at position 341 is known to result in a decreased maximal 
velocity in enzyme activity, perhaps by hindering tertiary structure formation.68· 78· 79 
The loss of the Taql restriction enzyme site indicates the presence of the S2 allele 
(NA T2*6A), resulting from the mutation at position 590 (G > A), accompanied by a 
silent one at 282 (C > T). The effect on the protein is a decreased stability, found by 
Blum and Grant et a/.75 using COS-1 cells, and confirmed by Hein and Ferguson et 
a/.78 when cloning into E.coli. This defect is brought about by the amino acid 
substitution of arginine197 for glutamine.68• 78• 79 
The S3 (NAT2*7B) mutation is evident after digestion with BamHI due to a point 
mutation at position 857 (G > A), causing the substitution of glycine286 for glutamine. 
This mutation causes a decreased stability and increased affinity in the resultant 
enzyme. It would appear that the instability outweighs the increased affinity for the 
substrate, thereby reducing enzyme activity.68 The coincident silent mutation at 282 
(C > T) seems to have no (additional) effect.68· 78 
The M4 ( NAT2*14) allele (referred to in this report as S4 for convenience) is absent 
in Caucasians and was only discovered later in 1993 by Bell et al, after obtaining 
discordance between genotype and phenotype.80 This allele is the result of a point 
mutation at position 191 (G > A), altering codon 64 and replacing arginine64 for 
glutamine. It has been proposed that this substitution could inhibit the formation of 
the acetylated enzyme intermediate in the acetylation process. Hein and Ferguson et 
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al. propose that since it occurs within the highly conserved Arg64 - Gly65 - Gly66 -
Trp67 - Cys68 motif in the protein and the active site is known to hinge on the 
presence of Cys68; the substitution of glutamine within this domain could hinder 
optimal binding.78·81 Grant and Hughes et al. propose that this amino acid 
substitution offers no impaired substrate affinity but contributes to reduced stability.68 
Upon studying alleles F (Allele 1 ), S2 (Allele 3) and S3 (Allele 2), Deguchi52 found 
that the levels of mRNA did not differ significantly between alleles. This suggests 
that the differences observed in enzyme activity are determined by the amount of 
protein present, and that the amount of protein is dictated by the protein stability. This 
was shown in cultured CHO cells, where levels of allele 1-dictated N-
acetyltransferase were high and allele 2- and allele 3-dictated N-acetyltransferase 
levels were low. 52 Grant and Eichelbaum et al. showed that the slow acetylator 
phenotype is due to the decreased level or absence of N-acetyltransferase in the 
human liver.82 
Table 4.1a.* Frequencies(%) of NAT2 acetylator alleles in different ethnic groups30 
Black, US 172 0.29 0.24 0.070 0.076 0.68 0.32 
White, US 98 0.41 0.34 0.020 0 0.76 0.24 
India 122 0.33 0.38 0.033 0 0.74 0.26 
Hispanic I 166 0.23 0.17 0.17 0.006 0.58 0.42 
Hispanic II 130 0.32 0.19 0.10 0.008 0.62 0.38 
Filipino 200 0.065 0.36 0.18 0 0.60 0.40 
Hong 140 0.057 0.31 0.16 0 0.52 0.48 
Kong 
Japanese 158 0.019 0.23 0.11 0 0.36 0.64 
Taiwanese 200 0.025 0.31 0.15 0 0.48 0.52 
Korean 170 0.018 0.18 0.11 0.011 0.32 0.68 
Samoan 50 0.040 0.34 0.020 0 0.40 0.60 
*Adapted from Lin et al (1994) 
Given the isoniazid acetylation polymorphism, population studies have been carried 
out to determine the epidemiology of NA T2 in different ethnic groups (see table 
4.1a.). Various authors have reported on numerous phenotypic studies. Lin and Han 
et al. have taken this epidemiology further, in that they have attempted to determine 
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the molecular epidemiology of these slow alleles and their ethnic distribution.30• 83 
From numerous population studies, they were able to determine the origins of 
mutation 857A (S3) to be Asian. 
Bell and Taylor et at.80 reported on the discovery of the M4 allele in an African-
American population (referred to as S4 in this report). In 372 Caucasian individuals 
enrolled in his study, not a single M4 allele was found. This allele appears to be of 
African origin.80 It has been known since the advent of phenotyping this trait, 12 that 
populations such as the Japanese exhibit a high proportion of rapid acetylators. A 
study in 51 Japanese individuals (1992) calculated the frequency of the rapid allele to 
be 72.5%,62 compared to 71 .05% found in 1961 by Sunahara and Urano et a/.11 
From the table above, the prevalence of rapid alleles in eastern populations is 
evident, compared to the predominance of slow acetylator alleles in Caucasians. 
The aim of this chapter is to offer further support for the validity of the assay 
developed to determine a patient's acetylator phenotype (using the method described 
in chapter one), as well as the markers used to determine phenotype (data presented 
in chapter two). Furthermore, this report will examine the NAT2 genetics within this 
geographically unique population. 
Being geographically, culturally and racially unique, this population, while the 
incidence of tuberculosis is high, remains relatively unstudied with regard to the 
isoniazid acetylation polymorphism. One study has been published, in which the 
trimodality of isoniazid elimination was conclusively reported in this population and 
allusions to the ethnic origins of this population made.37 Codominance of the rapid 
and slow alleles has also been shown previously, as well as in chapter 2 of this 
report. Although often reported , trimodality is not an established fact in the western 
scientific community, with many researchers still referring to heterozygous rapid 
acetylators, eliminating the intermediate group completely. 
In final support of the HPLC assay developed earlier, as well as the phenotypic data, 
this chapter aims to correlate the apparent phenotype with the determined genotype. 
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4.2. MATERIALS AND METHODS 
Each patient donated a sample of blood, which was collected in EDTA-coated tubes. This 
was used to extract and purify genomic DNA, which was then used for the specific 
amplification of the NA T2 gene sequences; the amplified DNA was then used to investigate 
the type of polymorphic N-acetyltransferase coded for in each patient. 
4.2.1. DNA Extraction from Human Nucleated Cells in Whole Blood 84 
This process is essentially a salting out procedure. 
1. Anticoagulated blood (7 ml) was poured into a 50 ml sterile tube. Approximately 30 to 35 
ml of ice cold Cell Lysis Buffer was added to the tube, before shaking vigorously 15 to 20 
times. 
2. The tubes were centrifuged at 3000 rpm using a Sorvall RT6000 refrigerated centrifuge for 
15 min at 4°C. 
3. Nuclei Lysis Buffer (15 ml) was used to resuspend the pellet. The solution was then mixed 
gently and Proteinase K solution (10 mg/ml) (Roche) was added to a final concentration of 
100 µg/ml. 
4. The tubes were incubated overnight at 37°C. This time period may be reduced by 
increasing the concentration of Proteinase K added and incubated at 45°C until all 
particulate matter has dissolved. 
5. After digestion was completed, 3-4 ml saturated NaCl (in excess of 6M) was added. The 
solution was mixed thoroughly, but gently. 
6. Again the tubes were centrifuged at 3000 rpm for 20 min at 4°C. 
7. The supernatant was transferred to 40 ml Absolute Ethanol (Merck), being careful to 
exclude all particulate matter from the protein pellet. If the Proteinase K digestion was 
successful, the resulting precipitate containing the DNA should be pure and white. 
Otherwise, it develops a brown hue indicative of residual protein. 
8. The precipitate was allowed to float to the surface before being removed with a sealed 
Pasteur pipette. Autoclaved 1.5ml polypropylene tubes were used to store the DNA. 
9. The DNA was washed with 500 µ180% ethanol. 
10. The ethanol was discarded and the DNA pellet dried at 37°C for 10 min, using a heating 
block (Techne Ori-block Model DB 3A, Techne). The dried DNA was reconstituted 
overnight in 1000 µI TE Buffer at 4°C. 
Note: Certain samples gave DNA yields, which were too low to observe and collect visually. 
These tubes were mixed after adding the ethanol, and centrifuged at 3000 rpm for 1 O min. 
This was done to pellet any DNA present. If visible after centrifugation, 500 µI TE was added 
and allowed to resuspend at 4°C. 
Chapter Four: The Genetics of N-Acetyltransferase 2 
Cell Lysis Buffer: 




10 mM Tris, pH 7.6 
Nuclei Lysis Buffer: 
400 mM NaCl 
10 mM Tris, pH 8.2 
2 mM EDTA, pH 8.2 
1%SDS 
4.2.2. Determination of DNA Concentration 85 
80 
TE Buffer: 
10 mM Tris, pH 7.5 
2 mM EDTA, pH 7.5 
Ten microlitre aliquots of each DNA solution were redissolved in 490 µI sterile water. This 
introduces a dilution factor of 2.5. 
The optical density (OD) was read at two wavelengths to determine DNA content and purity 
using a spectrophotometer (Milton Roy Spectronic 1201 ). The initial reading at 260 nm allows 
the calculation of the DNA concentration. An OD reading of 1 unit represents either 50 µg/ml 
double stranded DNA, 40 µg/ml single stranded DNA or RNA, or 20 µg/ml single stranded 




gives an indication of the DNA purity. According 
to Sambrook and Fritsch et al. (1985)85 pure DNA would give a ratio equal to 1.8, pure RNA, a 
ratio equal to 2 and any protein contamination, a ratio of less than 1.8. All calculations were 
carried out using the Beer Lambert Law: 
A= sci 
A = Absorbance at 260nm 
e = extinction coefficient 
c = concentration 
I = cuvette width ( 1 cm) 
given that 1 µg/ml solution of DNA gives an OD reading of 50.85 
Using the above method, the concentration of DNA in each sample could be determined as 
well as the yield, knowing the volume of TE Buffer used to resuspend each sample. 
4.2.3. Determining DNA Integrity using Gel Electrophoresis 
A 0.7% agarose gel was prepared in order to check the purity of the DNA collected visually. 
Two hundred millilitres of 1 X TBE buffer (0.09M Tris-borate, 0.002M EDTA) was used to 
dissolve 1.4 g of FMC LE agarose (Seakem, FMC Bioproducts, Rockland, Maine, USA). The 
agarose-TBE suspension was heated to dissolve the powder, according to the manufacturer's 
instructions. The gel was run in 1 X TBE buffer, using apparatus prepared in-house connected 
to a BioRAD Model 200/2.0 power supply. All samples were loaded in 1 µg aliquots, using 
the results from the spectrophotometry to calculate loading volumes. Promega's Blue/Orange 
6X tracking dye was used to monitor the running of the gel. Two microlitres of the dye was 
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added to each DNA sample. 
A DNA standard, in the form of 4 µI (1 µg) uncut lambda DNA (0.25 g/ml, BM) added to 2 µI 
tracking dye. The gel was run at 100 volts for approximately 60 min until the Bromophenol 
Blue dye front reached the end of the gel. 
The bands of DNA were visualised by adding ethidium bromide to the staining buffer (1 X 
TBE) to a final concentration of 0.5 µg/ml. The gel was shaken in this solution for 10 min., and 
the DNA visualisation was achieved by ultraviolet transillumination . 
5 X TBE Buffer (2000 ml) 
108 g Tris Base (Saarchem) 
55 g boris acid powder (Saarchem) 
40 ml 0.5 M EDTA (pH 8) 
4.2.4. Polymerase Chain Reaction (PCRJ50 (modified by Dept. Medical Biochem, US) 
Genomic DNA from the whole blood was amplified using the PCR technique. A stock solution 
of the reaction mixture was made up consisting of the components listed below. Each 60 µI 
aliquot consisted of: 
8 µI 2.5 mM PCR Nucleotide Mix (Bioline, London, UK) 
10 µ110 X PCR Buffer (GibcoBRL, Life Technologies) 
4 µI 50 mM MgCl
2 
(GibcoBRL, Life Technologies) 
0.3 µI Taq Polymerase I (5 U/µI) (GibcoBRL, Life Technologies) 
0.5 µI Nat-Hu 14 (Oligonucleotide primer) (Integrated DNA Technologies, Coralville, IA, USA) 
0.5 µI Nat-Hu 16 (Oligonucleotide primer) (Integrated DNA Technologies, Coralville, IA, USA) 
36.7µ1 Sterile Milli-Q water 
The primers used in PCR:50 
Nat-Hu14: 5'-GACA TTGAAGCAT A TTTTGAAAG 
Nat-Hu 16: 5'-GATGAAAGTA TTTGATGTTT AGG 
The MgCl
2 
and Taq Polymerase I aliquots were added last in order to prohibit non-specific 
activity by the polymerase. The DNA template aliquot (to be amplified) was made up to 40 µI 
using sterile water. By adding 60 µI of the PCR reaction mixture, the reaction volume totalled 
100 µI. It was not necessary to lay mineral oil over the top of the solution in order to prevent 
evaporation and maintain the ion concentrations because the all the amplification reactions 
were carried out in a Perkin Elmer GeneAmp 2400 PCR system, which has an integrated 
heated lid, normalising the temperature environment. 
The polymerase chain reaction consisted of an initial denaturation step of 94°C for 5 minutes, 
followed by 30 cycles of 94°C for 45 seconds (denaturation), 56°C for 50 seconds 
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(reannealing) and 72°C for 1 :20 minutes (elongation). The process ended with a final 
elongation step of 15 minutes at 72°C. The samples were kept at -20°C until required for 
digestion. 
A positive control sample - consisting of genomic DNA from an unrelated patient (supplied by 
CJ Werely, Dept. of Medical Biochemistry, Univ. of Stellenbosch) - was included in each 
amplification experimenUreaction. The negative control was made up of 40 µI sterile water 
and 60 µI reaction mix. Thus, if any component of the reaction mix were not functioning, the 
positive control would not amplify; similarly, any DNA contamination present in the 60µ1 
reaction solution would show up in the negative control. 
4.2.5. Determining PCR Quality 
A 5 µI aliquot of each amplified sample tube/reaction was assayed on a 0.7% agarose gel in 
order to verify whether the PCR was successful. Again the running and staining buffers were 
1X TBE. Intensities of the DNA bands were measured against a standard known to contain 
previously amplified NAT2 DNA (prepared by Cedric Werely, Dept. Medical Biochem, US). 
Later, pooled positive PCR controls were used, and served just as well. An aliquot of the 
1 OObp DNA ladder (Promega) (5µ1) served as molecular weight markers, each band 
increasing by 1 OObp in length, the 500bp fragment being twice as intense. Bromophenol Blue 
was added to each sample prior to running. Following the addition of ethidium bromide (0.5 
µg/ml), the bands were visualised under UV, having run the gel at 1 OOV until the 
Bromophenol Blue dye front to the end of the gel. 
4.2.6. Restriction Enzyme Digestion50 (Adapted by Dept. Medical Biochem, US) 
Each amplified DNA sample was restricted with four different enzymes in order to determine 
the allelic genotype, as caused by the various point mutations, resulting in slow acetylator 
alleles. Each reaction required 15.7 µI DNA template, taken from the amplified aliquots. To 
this, 3.3 µI of enzyme reaction mixture was added, making up a total volume of 18 µI. This 
volume was split after initial digestion with the enzymes BamHI, Kpnl and Mspl; an 8 µI 
aliquot was removed for an additional Pstl digestion. This double digestion protocol was 
developed by CJ Werely, Dept. of Medical Biochemistry, Univ. of Stellenbosch,_and utilised 
because it gave a better resolution of the profile of bands generated by the above enzymes, 
thereby making the scoring of the allele profiles much easier and more reliable. The 
remainder of the initial sample digest (1 OµI) was analysed on a 2% Metaphor® agarose (FMC 




1.8 µI 10X SuRE/Cut Buffer L (BM, Roche Molecular Biochemicals) 
1.5 µI Msp I (10U/µI; BM, Roche Molecular Biochemicals) 
1.8 µI 1 OX Su RE/Cut Buffer L (Amersham, Pharmacia) 
1.5µ1 Kpn I (10U/µI; Amersham, Pharmacia) 
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Sam HI: 1.8 µI 10X SuRE/Cut Buffer B (BM, Roche Molecular Biochemicals) 
1.5 µI Bam HI (10U/µI; BM, Roche Molecular Biochemicals) 
83 
All the above reactions were incubated overnight at 37°C using a heating block set yo 37°C 
(Techne Ori-block Model DB 3A, Techne). Pstl digestions were also incubated overnight at 
37°C. This was possible due to the fact that each of the enzymes had been tested for non-
specific endonuclease activity over 24 hours. 
The agarose gel was prepared using the rapid microwave instructions of the manufacturer. 
The agarose was slowly added to the buffer while swirling, in order to prevent the agarose 
from clumping. Having added all the agarose, the solution was dissolved using 100% power 
on the microwave for 35 seconds. Upon evidence of foaming, heating stopped until the 
bubbles subsided. This was carried out until no further foaming occurred, indicating total 
dissolution. The gel was poured, using a mini-gel apparatus and allowed to set at room 
temperature for 20 minutes. Thereafter the gel was chilled at 4°C for thirty before loading the 
gel and running it at room temperature. Ten microlitres of each digestion was loaded onto the 
gel , with 1 µI tracking dye, consisting of Bromophenol Blue and Orange G. The gel was run at 
100V, until the Orange G dye front reached the end of the gel. Again , ethidium bromide was 
added to a final concentration of 0.5 µg/ml and allowed to stain for ten minutes. UV 
transillumination visualised the bands and the digests were scored. 
Pst I: 0.96 µI 10X SuRE/Cut Buffer H (Amersham Life Science) 
0.8µ1 Pst I (15U/µI ; Amersham Life Science) 
0.24 µI sterile water 
Taq I: 1.8 µI 10X SuRE/Cut Buffer B (BM, Roche Molecular Biochemicals) 
1.5 µI Taq I (1 OU/µI ; BM, Roche Molecular Biochemicals) 
This reaction was incubated at 65°C for 4 hours. Both of these digestions (the Taql and Pstl 
series) were run on a 5% polyacrylamide gel. 
4.2.7. Polyacrylamide Gel Electrophoresis (PAGE) 
Two protocols were used to run 5% PAGE. The first set were prepared according to the 
following guidelines: 
1.2 5ml 40% (w/v) Acrylamide/Bis Solution (19:1) (GibcoBRL Life Technologies) 
125 µI 10% Ammonium persulphate solution (Ammonium peroxidisulphate - BDH) 
2 ml 5XTBE 
6.6125 ml Sterile water 
12.5 µITEMED (NNN'N'-Tetramethylethylenediamine - BDH) 
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The second set, not having the stock Acrylamide/Bis Solution available, was prepared 
according to the guidelines presented in Current Protocols in Molecular Biology 2; Greene 
Publishing Associates and Wiley lnterscience; John Wiley and Sons (date unknown). 
6.334 ml Sterile H20 
2 ml 5 X TBE 
1.67 ml 29:1 Acrylamide/Bisacrylamide mix 
50 µI 10% Ammonium persulphate 
5 µITEMED 
The Acrylamide/Bisacrylamide Mix was prepared by adding 29 g of acrylamide to 1 g of 
Bisacrylamide and dissolving in 100 ml water. This was then filtered through a 0.22 µm filter 
and stored in darkness at 4°C. 
The gels were run using a Bio RAD Mini-Protean II Cell Gel Electrophoresis kit, connected to 
a Bio RAD Model 200/2.0 power supply. Four microlitres of the 100bp DNA ladder (Promega) 
was run alongside the samples, serving as a molecular weight marker. One microlitre of 
tracking dye was loaded to serve as a dye front. The gel was run in 1 X TBE at 1 OOV for 90 
min using BioRad gel apparatus, until the Bromophenol Blue dye front had run off the gel. 
Note: It was decided to load different digestion series onto the same gel, in order to compare 
band sizes between digests and samples of the same enzyme digestion. 
4.2.8. Silver Staining 86 Adapted for 10 X 6 cm gels 
The process of silver staining is preferred for DNA determination on polyacrylamide gels, 
because of its sensitivity. 
1. Fix the DNA gel by washing with 50 ml 7 .5% acetic acid at 37°C for 10 minutes. Rinse 
gel in water for 3 minutes at 37°C. Repeat this twice. 
2. Staining: 
a) Prepare 0.1 % silver nitrate solution (m/v) by dissolving 0.05 g silver nitrate in 50 ml 
water. Heat solution to 37°C at the beginnig\ng of the gel electrophoresis. Five 
minutes before using, add 75 µI 3% formaldehyde (to a working concentration of 
0.056%). This is adequate for a single 10 X 6 cm gel. 
b) Stain gel in this solution for 10 minutes. 
c) After staining, rinse gel very briefly in water at room temperature. 
3. Development: 
1. Prepare a 3% (m/v) solution of sodium carbonate. Chill the solution at -20°C prior 
to gel electrophoresis. Thus the working temperature should be± 8-10°C. Five 
minutes prior to use, add 75 µI formaldehyde solution and 1 OµI 40mM sodium 
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thiosulphate, yielding a working concentration of 8µm thiosulphate, to 50 ml 
sodium carbonate solution. 
2. Stain the gel with the solution until the desired resolution is obtained. Depending 
upon the freshness of the silver nitrate, this should take 2-5 minutes. This should 
be very closely monitored. 
3. When the desired resolution is obtained, add 50 ml chilled 7.5% acetic acid for 5 
minutes and wash finally in water to terminate development. Optimally, there 
should be minimal background noise, and this may be aided by not adding the 
developing buffer directly onto the gel, and swirling immediately and well. 
4. The gel may be dried or sealed in plastic to preserve and score the digests. 
4.2.9. Digest Scoring Protocol 
In order to score each subject according to the alleles present in their genome, it was 
necessary to set up a simple system for scoring these restriction enzyme digestions. Having 
decided to digest all the primary digestions, excluding that of Taql , with Pstl for visualisation 
purposes, all the digestions were run on 5% polyacrylamide gels and silver stained. The 
banding patterns were easily distinguished and alleles were assigned to each individual. 




- IOO bp 
100bp Marker No S1 Allele Single S1 Allele Homozygous S1 Alleles 
Figure 4.2.a. The specific banding patterns observed using Kpn I followed by Pst I. 




100bp Marker No S2 Allele Single S2 Allele Homozygous S2 Alleles 




1 OObp Marker No S3 Allele Single S3 Allele Homozygous S3 Alleles 
Figure 4.2.c. The banding pattern seen when NAT2 is cut with 8am HI, followed by Pst I. 





100bp Marker No S4 Allele 
c:::=:J 
Single S4 Allele Homozygous S4 Alleles 
Figure 4.2.d. The banding patterns using Msp I restriction enzyme, followed by Pst I. 
87 
The smaller fragments are more difficult to visualise when running the gel. The resulting 
banding patterns were assessed and correlated with the apparent phenotype, determined 
previously. Any discrepancies resulted in the genotyping being repeated. The 
occurrence/distribution of alleles was tested using the Hardy Weinberg equation for multiple 
alleles in population genetics. 
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4.3. RESULTS 
4.3.1. DNA EXTRACTION AND PURITY 
DNA from each patient sample was extracted using the salting out procedure 
described in section 4.2.1. DNA concentration was determined using the Beer 
Lambert Law. 
DNA Extraction Yields 
Subject Number 
Figure 4.3.1a. The gross DNA yields for each individual to be genotyped calculated using the 
Beer Lambert law. 
The range of yields was broad, extending from 910 µg/ml down to 17.5 µg/ml. This is 
related to the number of white blood cells present in the sample and could be 
indicative of the patient's immune response. Certain samples were difficult to extract. 
A DNA integrity gel was run in order to gauge the integrity of the extracted DNA, prior 
to PCR. Samples 4, 8, 20, 23, 24, 49, 52 and 107 were tested, having been pelleted 
during DNA extraction. 
Chapter Four: The Genetics of N-A cetyltrans/erase 2 89 
Loading order from left: 8, 20, 4, 23, 24, 49, 52, 107, A-DNA (250 ng), A-DNA (500 ng) and A-DNA (1000 ng). 
Figure 4.3.1 b. Testing the integrity of extracted DNA - A representative gel. 
All the above samples contain significant amounts of high molecular weight DNA, of 
good integrity suitable to undergo amplification (see figure 4.3.1a.). Standards of 
lambda DNA were also run. Sample 23 showed a considerable amount of smearing, 
indicative of sheared DNA. This sample was later discarded due to its failure to 
amplify. The absence of RNA is noted by the absence of a diffuse haze toward the 
end of the gel. 
Most samples do show smearing, indicating a certain amount of DNA-shearing, the 
DNA appears to be intact, even though concentration is low. 
4.3.2. DNA AMPLIFICATION 
DNA amplification utilised a rapid PCR method using primers specific to conserved 
sections of the NA T2 gene sequence. 
Samples, which failed to amplify after 4 attempts and were discarded, included 4, 8, 
23, 24, 68, 70, 75, 80 and 115. 
Below is a representative image of a gel run in order to check the amplification of 
each DNA sample, following the application of the rapid PCR method. In this batch, 
samples 24, 33 and 41 failed to amplify. This is shown by the absence of a band in 
columns 1, 9 (row 1) and 5 (row 2). Shearing is indicated by the haze near the end of 
the gel . 
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Loading Order: LEFT to RIGHT 
24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, standard marker 
37, 38, 39, 40, 41, 42, 43, 44, 45, 45, negative control, positive control , 
standard marker 
Figure 4.3.2a. PCR Amplification 
4.3.3 DNA RESTRICTION ENZYME DIGESTION 
Restriction enzymes Kpn I (S1), Taq I (S2), 8am HI (S3) and Msp 1 (S4) were used 
to identify slow mutant alleles. The technique used to ascertain each individual's 
NA T2 genotype worked well. Banding patterns specific to each enzyme and each 
allele were easily recognised, with the aid of transillumination. One hundred and two 
patients were successfully genotyped, although there were certain individuals whose 
genotype did not correlate with their phenotype. It became evident that, as the silver 
nitrate solution aged, the quality of the silver staining deteriorated. This was resolved 




Loading Order: LEFT to RIGHT 
1, 2, 3, 5, 6, 7, 9, 10, 11 , 12, 13, 14, 15, 100 bp DNA Ladder 
Figure 4.3.3a. PAGE of Taq I digests 1: Samples 1-15 
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Lanes 1 O and 11 are evidence of S2 heterozygotes, displaying the fragment seen at 
approximately 500bp. A S2 homozygote would be missing the doublet as well as the 
lower band of 170bp. Arrows indicate the bands of interest, the bands appearing due 




Loading Order: LEFT to RIGHT 
(Bam HI) 6, 7, 9, 10; (Kpn I) 6, 7, 9, 10; (Msp I) 6, 7, 9, 10; 100 bp DNA 
ladder 
Figure 4.3.3b. PAGE of mixed digests: Samples 6-10 
In lane 2, it is evident that there has been a mutation, indicated by the absence of a 
restriction site resulting in a larger DNA fragment of approximately 400bp (indicated 
above using an arrow). This is indicative of the S3 allele, the presence of all the other 
common bands pointing towards an heterozygote. Lanes 5 and 7 present what is 
expected for a S1 heterozygote (also indicated using arrows), displaying an extra 
fragment of approximately 320bp, but there is no evidence of a S4 allele being 
present in any one of these samples. Certain digests were repeated following 
incomplete amplification. 
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4.3.4. ANALYSIS OF RESULTS 
Table 4.3.4i. The final allele allocations for 102 subjects, shown with predetermined 
apparent phenotype 
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Out of the 114 patients successfully phenotyped in chapter 3, 102 were successfully 
genotyped. Certain samples failed to extract, owing to the degradation of the white 
blood cells during storage and were discarded. Others did not amplify, although the 
DNA appeared to be of good quality and quantity. Each amplified sample was 
restricted and the banding patterns assessed to determine the presence or absence 
of each slow allele. No assay was implemented to assay for the wild type allele - this 
was assumed to be present in the absence of a slow allele. 
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Correlation between Genotype and Apparent Log (AclNH:INH) Ratio at 3 hours 
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Figure 4.3.4b. Genotype - Phenotype Relationship using the AUCT ratio model (n = 102). 
The correlation between phenotype and genotype is very close. The exact 
percentage of correlation was calculated to be 88.2% for both models, using extreme 
(difference from upper or lower limit> 0.2 units) outliers for the calculation . 
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Table 4.3.4ii. The incidence of all alleles according to accepted nomenclature87 
Trivial Name Genotype No. of Subjects 
Slow S1/S1 NAT2*5/NAT2*5 3 
S1/S2 NA T2*5/NA T2*6A 7 
S1/S3 NA T2*5/NA T2*7B 1 
S1/S4 NAT2*5/NAT2*14 2 
S2/S2 NAT2*6A/NA T2*6A 1 
S2/S3 NA T2*6A/NA T2*7B 3 
S2/S4 NAT2*6A/NA T2*14 4 
Intermediate S1F NA T2* 4/NA T2*5 30 
S2F NAT2*4/NAT2*6A 10 
S3F NAT2*4/NAT2*7B 7 
S4F NA T2* 4/NA T2*14 3 
Rapid FF NA T2* 4/NA T2*4 31 
From table 4.3.4ii, the incidence of the rapid acetylator allele is apparently similar to 
that of the slow acetylator allele. This indicates a marked Asiatic influence in this 
population, in contrast to Caucasian populations. The S4 (M4) allele is very rare in 
this population, as is the S3 allele - with no homozygotes being recorded, but they 
have been detected at low frequencies, concurring with Bell and Taylor et al. that S4 
may be of African origin.80 The predominant slow acetylator allele is S1, common in 
Caucasian populations, followed by S2, also relatively common. 
The specific frequencies of the slow acetylator alleles are S1 (50.0%); S2 (28.26%); 
S3 (11.96%) and S4 (9.78%). 
As seen below in figures 4.3.4c and 4.3.4d, the correlation of the marker values used 
to determine phenotype, as determined by phenotype and by genotype, is good. The 
increased size of the error bars for the genotype-governed allocations indicates the 
presence of non-correlators, but these are small and offer no significant overlap. The 
trimodality is still significant at p < 0.0001 (Mann Whitney test). 
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Figure 4.3.4c. The comparison between the trimodal splits governed by genotype and the 
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The Hardy Weinberg equation, suitable for multiple alleles, was applied to this 
d the incidence of each set of alleles measured to ensure that the 
nstituted a well-defined gene pool. 
population an 
population co 
The gene fre quency of the slow allele (s) was calculated to be 0.4368 for the 
pulation at Brewelskloof. This frequency value was then used to 




S2 : 2s (1-s) : (1-s)2 
Calculations 
individuals onl 
were later adjusted to consider a discrete population of coloured 
y, although this is not a true reflection of the tuberculosis population at 
hospital. Brewelskloof 
Table 4.3.4iii. The results of the application of the Hardy Weinberg equation and its 
principles 
A. Complete Sampled Population at Brewelskloof Hospital (n=102) 
or status Allele contributions Genotype frequencies Acetylat 
Phenotype Genotype slow (s) fast (1-s) Observed Calculated 
Slow SxSx 0.205 0.205 0.203 
Intermediate FSx 0.245 0.245 0.490 0.495 
Fast FF 0.304 0.304 0.302 
Total 0.450 0.549 1.00 1.00 
B. Eliminatin g the black and white participants (i.e. non-coloured individuals) (n=91) 
or status Allele contributions Genotype frequencies Acetylat 
Phenotype Genotype slow (s) fast (1-s) Observed Calculated 
Slow SxSx 0.187 0.187 0.188 
Intermediate FSx 0.247 0.247 0.494 0.492 
Fast FF 0.319 0.319 0.320 
Total 0.434 0.566 1.00 1.00 
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4.4. DISCUSSION 
The overall outcome of the genotyping procedure supported the phenotyping 
methods very well, emphasising the apparent trimodality of isoniazid acetylation, in 
this population, confirming the report of Parkin and Vandenplas et a/.37 An 88.2% 
correlation was evident between the assigned phenotype and the genotype of 
subjects (See figures 4.3.4a and b). This supports (a) the precision of the Log 
(AclNH:INH) value at three hours when used as a marker for acetylator status 
determination as well as (b) the usefulness of the assay, allowing a single sample to 
be analysed rapidly, without derivatisation, in order to estimate the individual's 
acetylator status. 
The DNA extraction was successful, extracting the DNA from all but two samples. 
The concentrations of DNA were varied, possibly relating to the severity of illness in 
the patient, extracting the DNA from the leukocytes in the blood. The overall integrity 
was good, with very little protein and RNA remaining in the sample. Having used the 
optical density as an indication of DNA purity, high OD2so values seemed to have little 
effect on DNA amplification. Those samples, which should have been heavily 
contaminated with protein, (data not shown) proceeded to amplify well and digestions 
were successful. Samples, which failed to amplify after numerous attempts, were 
discarded and the successful samples were followed though. Reasons for 
amplification failure might have included low DNA extraction yields (i.e. samples 4 
and 8) or a nucleotide substitution within the gene sequence complementary to the 
primer, inhibiting the primers from annealing optimally. 
The individuals, whose genotype did not appear to correlate with their phenotype, 
could have been misclassified due to the rapid and intermediate phenotype 
separation not being discrete. This is supported by the fact that not a single individual 
skipped a group - i.e. a slow misclassified as a rapid acetylator. Also, no digestion 
was performed by Ode 1, which has been known to indicate the presence of the 
mutated allele S1c, which would allow an intermediate acetylator to be classified as a 
slow acetylator genotypically.68 However, this allele is reported to be rare in the 
coloured population by Parkin and Vandenplas et a/.37 
Previously, it has been shown that non-correlation is a marker for new allotypic 
variants,80• 88 although no sequencing was performed on the individuals in question 
due to time constraints. Allusions to new acetylator alleles, although rare, have been 
made by Lin and Han et a/.30 This may account for a small proportion of discordance, 
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especially in this "new" population. Certain subjects did display anomalous bands 
upon restriction enzyme digestion. This may be an indication of further mutations 
within the population. Further work may be required to address that issue. 
Comparing the phenotypic trimodal split of individuals to the genotypic split, the Log 
(AclNH:INH) ratios are highly comparable (See figures 4.3.4c and d). The mean ratio 
for slow acetylators phenotypically is -0.6256 versus a genotypically determined ratio 
of -0.5726; intermediate acetylators display a phenotypic mean of 0.04189 compared 
to 0.03020 (genotypic); and rapid acetylators 0.3588 to 0.3354. 
Once again, the trimodality of the human acetyltransferase polymorphism has been 
demonstrated, taking into consideration the co-dominance of the fast and the slow 
alleles, constituting a separate acetylation group. Previous authors have 
acknowledged the existence of heterozygotes, but often classified those individuals 
as rapid heterozygotes. This report has confirmed the presence of a separate sub-
group of acetylators, those being the heterozygotes or intermediate acetylators. 
The predominance of intermediate acetylators may seem elevated in this population, 
but the prevalence of all alleles correlated closely with what was predicted by the 
application of the Hardy Weinberg equation, suitable for population genetics and 
multiple alleles. The exact correlations for the coloured population at Brewelskloof 
hospital for slow acetylators were 18.7% (18.8%), 49.4% (49.2%) for intermediate 
acetylators and 31.9% (32.0%) for rapid acetylators. The calculated percentages are 
represented in brackets. This determines the sampling population to be a well-
defined gene pool. 
One of the first papers published by Dufour and Knight et a/. 12 quoted gene 
frequencies in Caucasians, African-Americans and Japanese populations. Although 
the distribution was trimodal, the frequency of the slow allele in Caucasians and 
African-Americans was almost three times that of the rapid allele, whereas in this 
population the frequency of both alleles is highly comparable (43.4% vs. 56.6% in the 
coloured sampling population). This is an indication that this population draws from 
many influences. 
It has been stated previously that this population differs from the African-American 
population in its composition, due to the Eastern or Malay influence, boosting the 
incidence of fast alleles, which are known to predominate in these populations.67 Lin 
and Han et al. confirm that the S3 allele is Asiatic83 adding credence to the Malay 
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influence in this population. The incidence of this allele in this population is 12% of 
slow alleles. The S1 allele is highly prevalent (50% of slow alleles) and this indicates 
the Caucasian influence on this population.30 
4.5. FINAL CONCLUSIONS 
Genotyping the phenotyped patients served to support the findings in Chapters 2 and 
3. The developed assay was used to determine the drug levels, which were the used 
to calculate various pharmacokinetic parameters, which were subsequently used to 
determine the acetylator phenotype of the sampled patients. 
A correlation of 88.2% was noted between phenotype and genotype, and any 
discrepancy could be due to external, non-patient factors, such as impaired liver 
function or undetected alleles, such as S1c. The possibility of new allelic variants 
must not be ignored. This population is understudied, and may be the source of new 
slow acetylator mutations, as yet undiscovered, and these being responsible for the 
discordance observed. Further research is required. The gene pool was determined 
to be well-defined (i.e. random mating) and heterogeneous. 
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CHAPTER FIVE 
THE INFLUENCE OF ACETYLATOR STATUS 
5.1. INTRODUCTION 
Much debate has existed over the years as to whether acetylator status dictates the 
risk of isoniazid hepatotoxicity. Monoacetylhydrazine induces liver damage via the 
generation of a reactive metabolite.89• 90 It has been mentioned that the increased 
incidence of drug-induced hepatitis in certain population may be due to the increased 
incidence of viral hepatitis.91 Elevated serum aminotransferase levels associated with 
isoniazid administration, occur especially when administered with rifampicin, coupled 
with increased age and previous history of abnormal liver function. 92· 93· 94 
During a retrospective study performed by Mitchell and Thorgeirsson et al. (1975), a 
large number of subjects with drug-induced hepatitis were rapid acetylators. This 
lead to the hypothesis that rapid acetylators were more prone to hepatic injury, and 
that this injury was caused by prolonged exposure to an acylating agent, formed 
during microsomal activation of monoacetylhydrazine.95 
In contrast, a study conducted to assess the association between acetylator status 
and drug-induced hepatitis by Dickinson and Bailey et al. found that rapid acetylators 
had a very low risk of developing hepatitis (4%).96 Slow acetylators under 35 years of 
age and rapid acetylators above 35 years of age had a moderate risk (13%) and slow 
acetylators over 35 years had the highest (37%).96 This study assessed various 
contributing factors, such as age, mildly abnormal baseline liver enzymes, race, sex 
and concomitant therapy. The incidence of hepatotoxicity in this study are high when 
comparing them to those found in other studies. 
Mitchell's findings were disputed by many. A paper was published, which showed the 
lack of hepatotoxicity and acetylator phenotype correlation in 8 controlled clinical 
trials, involving 3 000 South Indian patients, measuring serum aspartate 
aminotransferase (AST) in 850 trial subjects and comparing this to their acetylator 
phenotype.36 
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Following the discovery that the enzyme responsible for detoxifying 
monoacetylhydrazine was the same one known to acetylate isoniazid,49 the theory of 
Mitchell and Thorgeirsson et al. 95 was brought into dispute. If a single enzyme were 
responsible for both of these processes, then the exposure of rapid compared to slow 
acetylators would be similar, and this was proven by assessing the urinary 
concentrations of isoniazid metabolites.9· 97• 98• 99 
Another theory followed. If a large dose (10 mg/kg) of isoniazid is administered to an 
individual, the enzyme responsible for metabolism (N-acetyltransferase 2) becomes 
saturated.49 Thus a large fraction of the administered dose will be available to the 
monooxygenase pathway, shown to produce hepatic necrosis via the formation of a 
reactive metabolite of acetylhydrazine.90 Administering drugs such as phenobarbital 
has induced the monooxygenase pathway.97 Concomitantly administering drugs, 
which induce the pathway with isoniazid, would cause an accumulation of 
acetylhydrazine, now made available to an induced monooxygenase pathway, ready 
to form a reactive acetylhydrazine metabolite and cause increased hepatic 
necrosis.97 The authors of this article (Lauterburg and Smith et al.) state that only 
individuals who possess remarkably slow acetylation capacity are at risk, thus 
accounting for the lower than expected incidence of hepatic injury in slow acetylators, 
when concomitantly administered with rifampicin. 97 
Subsequent to this paper, Jenner and Ellard published findings that the addition of 
rifampicin did not influence the incidence of drug-induced hepatotoxicity, citing 
among others, that the incidence of jaundice (1 %) was similar to previously 
documented cases prior to the introduction of rifampicin. 100 Peretti and Karlaganis et 
al. added another dimension to this debate - showing that the administration of 
isoniazid does tend to inhibit the acetylation of monoacetylhydrazine, possibly 
allowing a greater proportion to become available to the monooxygenase pathway. 101 
There has been no consistent evidence that the combination of rifampicin and 
isoniazid is particularly hepatotoxic in man.102 
A recent study in Japan correlated elevated serum aminotransferase levels with slow 
NAT2* genotype. The criteria for determining elevated levels were that they had to be 
1.5 X upper limit of normal and 2 X level prior to administration. Aminotransferase 
levels were taken at 0, 2, 4, 8 and 12 weeks. Each study population subgroup (i.e. 
acetylator phenotype) was homogeneous in terms of race, sex and age, coupled with 
the fact that the genotype spread was predicted by the Hardy-Weinberg Law, there 
was a 100% incidence of raised aminotransferase levels in slow acetylators. 94 There 
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have been numerous previous reports of elevated serum aminotransferase activity, 
but it has also been reported that these levels returned to normal after continuing 
therapy.93• 103 In the instance of hepatotoxicity in individuals receiving isoniazid 
chemotherapy, vigilance is necessary due to the likelihood that levels will return to 
normal and remain normal after therapy continues.103 It has been suggested that the 
outcome of hepatotoxicity could be fatal if the patient has been receiving isoniazid 
therapy for more than two months without vigilance on the part of the clinician .104 
A distinction should be made between raised levels and levels which are too high to 
tolerate. Treatment guidelines state that therapy should only be discontinued if the 
AST level is three times normal, provided the patient remains asymptomatic. 
Clinically overt hepatitis necessitates the complete discontinuation of treatment. 105 
Table 5.1 i. The incidence of hepatotoxicity during a series of studies run by the 
British Medical Council. 103 
Britain SHP 444 5 (5) 1 
n=2 SHE 116 1 (0) 1 
India SHP 519 9 (9) 2 
n=5 SH_. 78 0 0 
HT 75 2 (2) 3 
East Africa SHT 1665 10 (10) 1 
n=5 HP 125 2 (0) 2 
Hong Kong HP 100 1 (1) 1 
HT 150 8 (8) 5 
Singapore SHT 225 8 (6) 4 
SH 131 2 (1) 2 
International SHT 3563 15 (2) 0.4 
n=2 SH 2394 5 (1) 0.2 
* Values in brackets indicate cases of jaundice 
** Drugs administered daily - Abbreviations: S = streptomycin, H = isoniazid, P = para-aminosalicylic 
acid, E = ethambutol , T = thioacetazone 
*** Regimen given biweekly 
**** All regimens lasted over 12 months, except the international studies (8 and 12 weeks) 
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In terms of treatment outcome and for the purposes of this study, acetylator status is 
of no prognostic significance when treatment is given daily and only of doubtful 
significance when weak twice-weekly regimens are employed.48 
The variation occurring within the NAT gene loci results increased risk of certain 
types of cancers, depending upon the acetylation phenotype.68 The development of 
cancer depends upon a balance between two opposing enzymes - the activating and 
detoxifying enzymes for the compound and resulting metabolites. In the case of N-
acetyltransferase, if the enzyme is defective, other enzymes will predominate and 
from reactive species, which may lead to DNA binding and the formation of 
tumours.68 The tissue selectivity depends upon the destination of the reactive end 
product and the enzymes present, possibly increasing the DNA binding potential of 
the metabolite.68 This issue is still broad, with many feasible hypotheses. 
This chapter aims to gauge the effect of acetylator status on other patient 
parameters, such as the incidence of liver toxicity, markers used to gauge treatment 
progress (i.e. weight gain and clearance of sputum) and the gender distribution of 
acetylator status. 
Chapter Five: The fnjl11e11ce of Acetylator Status 106 
5.2. MATERIALS AND METHODS 
Liver function tests were performed once on all patients enrolled in the study on the day of 
pharmacokinetic sampling approximately two months after admission to Brewelskloof hospital 
for TB treatment. Blood for these tests was drawn between the 6 and 8 hours 
pharmacokinetic samplings via an indwelling canula and analysed by the chemical pathology 
laboratories at Groote Schuur hospital. Levels of liver enzymes indicate the extent, if any, of 
incurred liver damage, or the immediate state of the patient's liver. Significant cut-off points 
are used to gauge the severity of liver function impairment. This study aims to note the 
absolute elevation of liver enzyme levels, whether or not they are deemed clinically 
significant. 
Tests performed for liver function included alkaline phosphatase (AlkPhos), aspartate 
aminotransferase (AST), alanine aminotransferase {ALT) and total bilirubin. The levels were 
regarded as above normal limits if: 
• Alkaline phosphatase above 70 units, 
• AST and ALT above 25 units, 
• Total bilirubin above 17 units. 
From the phenotypic results regarding acetylator status, correlations were performed as to 
whether acetylator status had any effect upon the apparent liver function after two months of 
anti-tuberculosis drug therapy. 
Patient characteristics were obtained from Brewelskloof hospital with the patient's consent. 
The data included age, weight gain following two months of anti-tuberculosis therapy, sputum 
clearance after two months and patient gender. Sputum clearance was determined by 
culturing a sputum sample at two months post therapy initiation. 
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5.3. RESULTS 
As part of the pharmacokinetic study, into which this work fell, all patients were 
screened for raised liver enzyme levels, possibly in part caused by damage due to 
drug exposure. There is no direct correlation between isoniazid and raised liver 
enzymes. Normal fluctuations of liver enzymes are relatively common in individuals. 
Rifampicin may cause an increase in bilirubin, while all other concomitant 
medications may affect enzymes levels. The disease state of the patient may also be 
a mitigating factor. The incidence of raised liver enzymes was correlated with 
acetylator status. 
Liver Function as a function of Acetylator Status 
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Figure 5.3a. The distribution of raised liver enzymes 
As is evident from figure 5.3a, the incidence of raised liver enzyme levels was not 
related in any way to the assigned acetylator phenotype of the patient. 
The alkaline phosphatase levels were generally raised, although could only be 
regarded as mildly elevated. This in no way indicates isoniazid related liver damage, 
as alkaline phosphatase levels may be slightly raised due to alcohol intake or in 
young growing people. The AST and ALT levels are insignificant, neither displaying a 
two-fold or three-fold increase, necessitating treatment suspension .105 
C Rapid 
Chapter Five: The I,!fluence of Acetylator Status 




Figure 5.3b. The distribution of acetylator status by gender. 
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The split of acetylator phenotype according to gender indicated a majority of female 
patients with rapid phenotypes, and a majority of slow acetylators being male. The 
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Sputum clearance was implemented as one of the markers indicating possible TB 
treatment failure in the study. Sputum was collected from each patient at 2 months. 
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This was then assessed directly before being cultured. Rapid acetylators are known 
to fare worse than slow acetylators under certain conditions, such as once-weekly 
therapy.17• 55 The indication from figure 5.3c is that slow acetylators failed to clear the 
sputum more often than rapid acetylators. But this conclusion is not statistically 
significant, as the sample size is too small . 
Weight gain, another marker used to gauge response to treatment in the study, was 
not statistically related to acetylator status, using non-parametric statistics. In 
general, patients gained weight during the course of the two months they were in 
hospital, possibly because they were receiving regular meals with proper nutrition. 
Weight Gain per Acetylator Group 
0 2 3 4 5 6 
Mean Weight Gain (kg) 
Figure 5.3d. The distribution of acetylator status in terms of weight. 
When age was correlated with acetylator phenotype, there was no significant 
difference between the three acetylator groups. The mean ages for each group were 
37.0, 37.0 and 37.57 years for slow, intermediate and rapid acetylators respectively. 
7 
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Table 5.3i. Analysis of non-correlators for phenotyping confounders 
ID Age Weight AlkPhos AST ALT Total Bilirubin Pheno Geno G - P 
3 24 37.9 45 
33 33 48.7 68 
36 35 45.4 55 
43 59 47 69 
47 30 47 63 
65 43 
74 18 43.9 92* 
81 41 51 .8 59 
83 55 52 42 
94 35 34 194* 
99 44 60.3 47 
100 62 
111 50 41 81* 
119 49 62 38 
* Above normal limits 











































Although alkaline phosphatase levels were elevated in a significant number of 
patients, this elevation is not clinically significant. Guidelines state that only if levels 
are observed to be three times normal, is the asymptomatic patient at risk of 
hepatotoxicity .105 
Concomitant medication may influence the phenotypic assignation of a subject. 
Drugs such as prednisolone and ethanol have been observed to increase acetylation 
rates in slow acetylators.16 Only one patient was receiving prednisolone at the time of 
the sampling, patient 51, and she was classified as an intermediate acetylator, 
showing no discordance with the determined genotype. Alcohol abuse was not 
studied in this population, thus judging the effect of concomitant ethanol 
administration is not possible. 
No correlation was found with any patient characteristics and genotype/phenotype 
discordance. 
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5.4. DISCUSSION 
There are a significant number of individuals with mildly raised liver enzymes, but it is 
not a function of acetylator status, as demonstrated by the spread of cases between 
the three groups. 
Having sampled a large group of heterogeneous individuals, acetylator status does 
not play a role in dictating the incidence of raised liver enzymes. However, the 
incidence of alcohol abuse is high in this population, and perhaps this is masking the 
results. Another effect of the high incidence of alcohol abuse in this population would 
be the effect that ethanol has on acetylator phenotyping tests. Alcohol has been 
found to increase the rate of sulphadimidine acetylation, causing slow acetylators to 
be misclassified as rapid. 16 Having not determined the incidence of alcohol abuse in 
this population, it is not possible to quantitate the influence of ethanol. 
Using the data available, figure 5.3b. shows the distribution of acetylator status in 
each gender. From the graph, there is a higher prevalence of female rapid 
acetylators than male rapid acetylators and in contrast to this, a higher prevalence of 
slow male acetylators, compared to female slow acetylators. This trait is not sex-
linked, it is found on chromosome 8.75 However, it has been shown previously106 that 
females exhibited increased incidence of raised liver enzyme levels. Whether this 
could be due to the increased incidence of rapid female acetylators, as shown in this 
study, remains undetermined. 
Figure 5.3c. indicates that slower acetylators were seen to fail more often when 
clearing the sputum of viable mycobacteria. This would go against logic, as it is 
known that only the parent drug, isoniazid, is active against the bacterium. Slow 
acetylators would be subjected to a significantly prolonged exposure to this drug, 
thus benefiting more in terms of drug action. Compliance would also be a 
confounding factor, even within a hospital population. 
Weight gain (or change in weight) was not related in any way to the individual's 
acetylator status using a non-parametric Spearman correlation (figure 5.3d). 
For the pharmacokinetic study, a set of markers was decided upon to gauge 
response to treatment after two months of therapy. These included weight gain, 
sputum clearance {direct and culture), chest x-ray improvement and symptom 
alleviation. Using these as guides after this initial treatment, there is no correlation 
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between treatment response and acetylator phenotype. After a follow-up study, this 
may be possible, the only way to accurately assess outcome being after the 
completion of treatment. 
These markers do not serve as absolute indicators, because there are too many 
confounding factors. With weight gain, it would be difficult to assess this without 
considering the background of the patient. Receiving three full meals a day might not 
be possible at home, and this may outweigh the effect of the drug on clearing the 
symptoms. 
The role of concomitant medication may play a role in the discordance of phenotype 
with genotype. Prednisolone has been observed to increase the rate of acetylation in 
slow acetylators, leading to apparent discordance.16 
Upon analysing the non-correlators (Table 5.3i.), and looking for confounders of 
phenotypic/genotypic correlation, none of the factors analysed stood out as 
contributing factors to non-correlation. The ages and weights were evenly spread in 
terms of the entire dataset, and only one subject had overtly raised liver enzymes, 
indicating impaired liver function, which would cause rapid acetylators to be classified 
as slower acetylators. 
Many reasons could be cited for the discordance of these individuals. One could be 
that they do have slightly impaired liver function, impairing the ability of the liver to 
metabolise isoniazid, thus phenotypically expressing as a slower acetylator. But 
raised liver enzymes should indicate this. As mentioned previously, the allele S1c 
has not been assayed for owing to the rarity of it in this population personal comm with c. 
wereiy, but this could be contributing to a reduced phenotype compared to the 
genotype. Possibilities exist that would include new genetic alleles, but this should be 
investigated further. 
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5.5. FINAL CONCLUSIONS 
Acetylator status played no role in determining the incidence of raised liver enzyme 
levels in this population. The incidence of toxicity was not age-related, nor did it 
correlate with the weight gain observed after the first two months of drug therapy. 
There was a difference in the distribution of phenotype with respect to gender, female 
patients in general exhibiting a faster phenotype than males. Sputum clearance 
showed an insignificant trend towards favouring rapid acetylators at two months. 
No explanation in terms of patient related characteristics could be offered for the 
discordance of phenotype and genotype. This raises suspicion that there may be 
new allelic variants present in this population, responsible for reduced acetylation. 
Further genetic analysis (sequencing) is needed for this to be confirmed. 
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STUDY CONCLUSIONS 
DEVELOPMENT 
A plasma-based, high performance liquid chromatographic assay has been 
developed to measure the levels of isoniazid and N-acetylisoniazid in patients with 
tuberculosis. The assay utilises a simple solid phase extraction, simultaneously 
extracting both isoniazid and N-acetylisoniazid, before resolving the peaks using a 
CB column on HPLC. 
The assay has been validated in terms of its quality and has been determined to be 
specific, accurate, precise and linear, with detection limits of 300 ng/ml and 150 
ng/ml for isoniazid and N-acetylisoniazid respectively. The recovery is good and 
consistent, in excess of 70% for isoniazid and 90% for N-acetylisoniazid. The 
coefficients of variation were maintained below 10% and the coefficients of 
determination (r2) above 0.990. 
The result is a timesaving and effective assay, suitable for high volume 
pharmacokinetic analysis. 
IMPLEMENTATION 
In determining markers for acetylator phenotype, the ratio of AclNH:INH at three 
hours proved to be the most accurate, as well as the most convenient, displaying a 
trimodal distribution. 
Statistical analysis of the resulting pharmacokinetics revealed significant separation 
of the slow acetylators from the intermediate and rapid acetylators in all cases, with 
separation the latter two groups only evident in AUCT and AUCINF. Cmax and half-
life were bimodally distributed, failing to draw significance between the intermediate 
and rapid acetylators. Area under the curve (total and to infinity) was conclusively 
trimodal, significant difference being shown between all three phenotypes. Of 
concern is the significant reduction in AUC experienced by rapid acetylators, as well 
as the relative risk of rapid acetylators to fail to achieve therapeutic levels of 
isoniazid, in this population even while dosing for weight. Analysis of the elimination 
rate constant for isoniazid in each individual indicated the codominance of the alleles, 
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in that the prediction of the intermediate mean rate constant could be made within 
7% of the observed mean. 
VALIDATION 
Genotypic analysis served to support the phenotypic criteria for acetylator status 
determination, as well as the assay development. The assay was developed to 
determine plasma levels of isoniazid and N-acetylisoniazid, which were used to 
determine the phenotypic characteristics of acetylator status in patients with 
tuberculosis. 
A correlation of 88.2% was observed between phenotype and genotype. Discordance 
could be due to patient characteristics or the evolution of new allelic variants. Further 
investigation into DNA sequencing is required. The distribution of alleles correlated 
closely to that predicted by the Hardy-Weinberg equation, proving the population to 
be a heterogeneous sampling of a well-defined gene pool. 
ACETYLATOR STATUS INFLUENCE 
Various patient factors were investigated in terms of acetylator status. It was found 
that acetylator status played no role in determining the incidence of liver toxicity. 
Acetylator status was not age-related, nor did it influence the weight gain of patients 
within the first two months of treatment. There was a difference in the distribution of 
phenotype with respect to gender, female patients in general, exhibiting a faster 
phenotype than male patients. Sputum clearance showed an insignificant trend 
towards favouring rapid acetylators after two months of therapy. 
No explanation could be offered for the discordance of phenotype with genotype, in 
terms of patient characteristics, confirming the suspicion that the discordance could 
be related to new allelic variants within this population, requiring DNA sequencing. 
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APPENDIX I 
PATIENT CONSENT FORMS AND DATA COLLECTION 
Subject no. __ _ 
CONSENT TO PARTICIPATE IN A CLINICAL STUDY 
PHARMACOKINETICS OF ANTITUBERCULOSIS DRUGS IN PATIENTS 
RESPONDING POORLY TO THERAPY. 
I agree to take part in the above-mentioned study. 
I understand that the study is to improve the understanding of how drug levels, 
tuberculosis sensitivity to drug levels and other individual patient factors influence the 
effectiveness of TB treatment. 
I understand that the study involves the documentation of personal and treatment 
details, a physical examination, collection of blood samples (about 25ml of blood), a 
chest x-ray and sputum collection. Laboratory evaluation of the blood will include 
testing for the HIV virus, haematological, biochemical and immunological status. 
In addition, on one or three occasions: I will fast overnight before serial blood 
samples totalling about 110ml will be taken over a period of eight hours after the 
swallowing of my medication the next day. A cannula will be inserted into an arm vein 
for the collection of these blood samples. Three, 2hour urine collections will also be 
collected during the 8 hour period(s). 
I understand that the study also involves the collection of a sputum samples at 2 
months and at 6, 9, 12, 18 and 24 months after the initiation of treatment at 
Brewelskloof Hospital. I understand that I am obliged to present at the clinic to which 
I am referred at the required times. 
I understand that participation in the study does not hold any treatment benefit. 
I have been given the opportunity to ask any questions concerning the study and am 
satisfied with the explanation or advice given. 
I have truthfully answered all the questions necessary to complete the data collection 
forms. 
I agree to comply with the instructions given to me by the investigators or their 
assistants. 
I understand that the information collected will be treated confidentially, and that only 
the investigators and their assistants will be able to link any of the information 
collected to my name. 
I understand that I am free to withdraw from the study at any time without prejudice to 
me for doing so. 
I am aware that this study has been subjected to review by an ethics committee. 
NAME OF SUBJECT SIGNATURE DATE 
NAME OF INVESTIGATOR SIGNATURE DATE 
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Subject no. : __ 
TB PROGRESS RA TING AT 2 MONTHS TOT AL SCORE: /20 
1. SPUTUM 
Direct sputum microscopy 
~ 2 months +++ ++ 
+++ 0 0 
++ 0 0 
+ 1 0 
Scanty 2 1 
- 4 4 
Culture 
~ 2 months 1-7 days >7-14 days 
1-7 days 0 0 
>7-14 days 0 0 
>14-21 days 1 0 
>21 days 2 1 
Negative 4 4 
If only direct microscopy done; multiply score by 2 













If initial direct microscopy was negative, use culture score and multiply by 2 














If smear remains positive, but culture is negative at 2 months; allocate a score of 8 
2. CHEST X-RAY SCORE: 
chest x-ray on admission is compared with that after 7 to 8 weeks of DOT as an in-patient 
and assessed by 3 Medical Officers independently. 
UnchanQed or worse 0 
Some improvement 2 
Obvious improvement 4 
Resolved 6 
3. WEIGHT SCORE: 
weight on admission is compared with that after 7 to 8 weeks of DOT as an in-patient. 
Decreased, static or increased <1 kQ 0 
Increase < 1 kq up to 10% 2 
Increase> 10% up to 15% 3 
Increase> 15% 4 
4. SYMPTOMS: SCORE (max 2): 
symptoms on admission are compared with those after 7 to 8 weeks of DOT as an in-
patient. 
No improvement Some Markedly improved or 
improvement resolved 
Cough/ Dyspnoea/ 0 1 2 








Subject no: Date: 
Ward: Investigator: 
Folder number: Date of admission: 
Name: 
Age: Sex: I male I female I 
Race: I A I B I C I W I Other I 
Home address: 
Place of birth: 
ELIGIBILITY: 
Pulmonary tuberculosis confirmed by positive sputum for M. 
tuberculosis: direct microscopy or culture 
Informed consent 
consent to HIV testing 
~ 18 years 
On daily inpatient treatment with rifampicin, isoniazid, pyrazinamide, +l-
ethambutol, +/- an aminoglycoside for 8 weeks at Brewelskloof Hospital. 
not critically ill and no contraindications to multiple blood sampling 
no known resistance to isoniazid or rifampicin 
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Subject no. __ 
PK SAMPLING / ADVERSE EVENTS FORM 
DATE of PK sampling: I I 
Drug administration: 
Drug Dose Exact admini- Formulation / Batch no. Exp. date 






Blood sampling times: 
Sample Hrs after drug administration Exact time of sampling 
(hh:mm) 
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APPENDIX Ill 
PHARMACOKINETIC DATA FOR ISONIAZID AND N-ACETYLISONIAZID 
Subiect Rsa Corr<x:v) Tmax Cmax 
1 0.9936 -0.9968 1.0000 5.3887 
2 0.9164 -0.9573 3.0000 5.1442 
3 0.9329 -0.9658 2.5000 4.6536 
4 0.9758 -0.9878 1.5000 3.7231 
5 0.9814 -0.9906 1.5000 7.0659 
6 0.9970 -0.9985 0.5000 7.6100 
7 0.9596 -0.9796 1.5000 4.9407 
8 0.9542 -0.9768 1.0000 7.4252 
9 0.9935 -0.9968 0.5000 10.9152 
10 0.8459 -0.9197 1.0000 2.8605 
11 0.9654 -0.9825 1.5000 4.0330 
12 0.9918 -0.9959 2.5000 8.3571 
13 0.9658 -0.9827 3.0000 5.4547 
14 0.9947 -0.9974 1.0000 6.6103 
15 0.9515 -0.9754 1.5000 5.7446 
16 0.9913 -0.9957 1.0000 5.9724 
17 0.9845 -0.9922 2.0000 7.0282 
18 0.9553 -0.9774 1.5000 4.5148 
19 0.9837 -0.9918 1.0000 5.9599 
20 0.9991 -0.9996 0.5000 8.4863 
21 0.9218 -0.9601 2.0000 2.8392 
22 0.9899 -0.9949 1.5000 6.4308 
23 0.9386 -0.9688 1.5000 3.5580 
24 0.9979 -0.9989 1.5000 10.3290 
25 0.9862 -0.9931 1.0000 9.9238 
26 0.9816 -0.9908 1.5000 6.9087 
27 0.9992 -0.9996 4.0000 10.7368 
28 0.9496 -0.9745 1.5000 7.6503 
29 0.9884 -0.9942 1.5000 8.5263 
30 0.9139 -0.9560 1.0000 8.4830 
31 0.9803 -0.9901 1.5000 4.2883 
33 0.9999 -0.9999 0.5000 9.3776 
34 0.9304 -0.9646 1.0000 10.1407 
35 0.9970 -0.9985 1.0000 7.1503 
NCA Data - [C:\WINNONLN\INHFIN.WDO] 
Final Parameters 




































































































































Subiect Rsa Corr(x:v) Tmax Cmax 
36 0.9432 -0.9712 0.5000 6.5205 
37 0.9970 -0.9985 1.0000 4.9756 
38 0.9934 -0.9967 1.5000 6.4888 
39 0.9243 -0.9614 1.5000 2.8561 
40 0.9413 -0.9702 1.0000 3.9474 
41 0.9999 -0.9999 0.5000 5.1593 
42 0.9907 -0.9953 2.0000 3.9665 
43 0.9966 -0.9983 2.0000 3.0935 
44 0.9698 -0.9848 1.0000 8.1111 
45 0.9473 -0.9733 1.0000 4.0809 
46 0.9950 -0.9975 2.5000 3.3985 
47 0.9999 -1.0000 1.5000 3.2941 
48 0.9489 -0.9741 2.5000 2.6867 
49 0.9992 -0.9996 1.0000 3.2379 
50 0.9299 -0.9643 0.5000 7.5890 
51 0.9647 -0.9822 1.0000 3.4850 
52 0.9911 -0.9955 2.0000 5.1749 
53 0.9502 -0.9748 1.0000 2.3713 
54 0.9073 -0.9525 2.5000 3.1354 
55 0.9476 -0.9735 2.5000 4.0549 
56 0.9520 -0.9757 0.5000 9.1423 
57 0.9380 -0.9685 1.5000 3.6322 
58 0.9552 -0.9773 1.0000 6.6341 
59 0.8910 -0.9439 1.0000 4.3935 
60 0.9590 -0.9793 2.5000 3.3330 
61 0.9234 -0.9609 1.0000 3.0778 
62 0.9918 -0.9959 2.0000 3.4389 
63 0.9970 -0.9985 0.5000 3.7896 
64 0.9192 -0.9587 1.0000 5.4784 
65 0.9817 -0.9908 0.5000 7.9556 
66 0.9654 -0.9826 1.0000 3.8597 
67 0.9483 -0.9738 2.0000 4.2376 
68 0.9894 -0.9947 2.0000 3.8346 
69 0.9518 -0.9756 1.5000 4.8678 
NCA Data - [C:\WINNONLN\INHAN.WDO] 
Final Parameters 


































































































































Subiect R~ Corr<x:vl 
70 0.9862 -0.9931 
71 0.9874 -0.9937 
72 1.0000 -1.0000 
73 0.9857 -0.9928 
74 0.9996 -0.9998 
75 0.9779 -0.9889 
76 0.9533 -0.9764 
77 0.9506 -0.9750 
78 0.9993 -0.9996 
79 0.9772 -0.9885 
80 0.9989 -0.9994 
81 0.9455 -0.9724 
83 0.6943 -0.8333 
84 0.9825 -0.9912 
86 0.9997 -0.9998 
88 0.9984 -0.9992 
89 0.9798 -0.9898 
90 0.9964 -0.9982 
91 0.9852 -0.9926 
92 0.9263 -0.9624 
93 1.0000 -1.0000 
94 0.9999 -1.0000 
95 0.9915 -0.9957 
96 0.7711 -0.8781 
97 0.9675 -0.9836 
98 0.9804 -0.9901 
99 0.9886 -0.9943 
100 0.8593 -0.9270 
101 0.9466 -0.9729 
102 0.8567 -0.9256 
103 0.9274 -0.9630 
104 0.9134 -0.9557 
105 0.9722 -0.9860 




































NCA Data - [C:\WINNONLN\INHAN.WDO] 
Final Parameters 





































































































































Subiect R~ Corr(x:v'\ Tmax 
108 0.9433 -0.9713 1.5000 
109 0.9725 -0.9862 1.0000 
110 0.9165 -0.9574 0.5000 
111 0.9777 -0.9888 0.5000 
112 0.9899 -0.9949 1.5000 
113 0.9468 -0.9730 0.5000 
114 0.9884 -0.9942 2.0000 
115 0.9609 -0.9802 2.0000 
116 0.9797 -0.9898 1.0000 
117 0.9991 -0.9995 1.5000 
119 0.9813 -0.9906 1.0000 














NCA Data - [C:\WINNONLN\INHFIN.WDO] 
Final Parameters 














Lambda z t1/2 Lambda z AUCINF( observed) 
0.1878 3.6914 29.9352 
0.1352 5.1260 24.1285 
0.2223 3.1179 27.0032 
0.1764 3.9288 22.3326 
0.1194 5.8063 38.0977 
0.2381 2.9115 25.5265 
0.1835 3.7768 34.9939 
0.1551 4.4680 44.9160 
0.1997 3.4701 19.1130 
0.1834 3.7792 50.3177 
0.1847 3.7526 28.3580 





























Sub;ect Rsa Corr<x:vl Tmax Cmax 
1 0.9944 -0.9972 2.0000 5.3053 
2 0.9649 -0.9823 4.0000 3.7300 
3 0.9836 -0.9918 3.0000 5.5449 
4 0.9787 -0.9893 2.0000 3.3603 
5 0.9978 -0.9989 3.0000 4.0778 
6 0.9774 -0.9886 1.5000 3.5997 
7 0.9883 -0.9941 2.5000 3.5029 
8 0.9417 -0.9704 3.0000 3.1050 
9 0.7808 -0.8837 1.5000 3.8285 
10 0.9935 -0.9968 2.5000 4.9739 
11 0.9977 -0.9988 2.5000 3.0789 
12 0.9576 -0.9786 4.0000 2.9847 
13 0.9419 -0.9705 4.0000 0.9662 
14 0.8681 -0.9317 4.0000 1.1012 
15 0.9981 -0.9990 3.0000 6.5541 
16 0.9366 -0.9678 2.5000 3.4148 
17 0.9930 -0.9965 2.0000 4.0186 
18 0.9731 -0.9865 1.5000 4.5465 
19 0.9866 -0.9933 3.0000 3.9463 
20 0.9993 -0.9996 2.5000 1.4584 
21 0.9900 -0.9950 2.0000 4.1730 
22 0.9235 -0.9610 3.0000 1.3370 
23 1.0000 -1.0000 2.0000 4.3175 
24 0.9936 -0.9968 3.0000 3.6368 
25 0.9997 -0.9999 4.0000 4.0826 
26 0.9134 -0.9557 3.0000 1.2279 
27 0.9639 -0.9818 1.5000 2.9286 
28 0.9998 -0.9999 3.0000 8.2659 
29 0.9647 -0.9822 3.0000 6.2287 
30 1.0000 -1.0000 2.5000 6.4369 
31 0.9990 -0.9995 3.0000 10.1893 
33 0.9979 -0.9989 2.5000 7.0074 
34 0.9913 -0.9957 2.0000 7.6714 
35 0.9799 -0.9899 3.0000 6.5404 
NCA Data - [C:\WINNONLN\AINHFIN.WDO] 
Final Parameters 
No. nnints Lambda z AUClast Lambda z 
4.0000 29.8147 0.2056 
3.0000 19.0897 0.1067 
3.0000 31.2785 0.1543 
6.0000 17.9882 0.1320 
3.0000 22.9544 0.1994 
3.0000 20.5945 0.1750 
3.0000 17.9711 0.2287 
4.0000 18.4936 0.1208 
5.0000 24.7796 0.1248 
5.0000 23.6907 0.2266 
3.0000 13.7186 0.3097 
3.0000 13.0450 0.2323 
3.0000 5.4674 0.0897 
3.0000 6.8043 0.1363 
3.0000 38.1290 0.1549 
5.0000 17.9141 0.2698 
4.0000 21.5578 0.1741 
5.0000 19.4982 0.2510 
3.0000 22.2113 0.1908 
3.0000 8.3077 0.2138 
3.0000 18.4251 0.3875 
3.0000 6.6161 0.1146 
3.0000 28.3785 0.0964 
4.0000 21.8658 0.0776 
3.0000 25.3158 0.1343 
4.0000 8.3951 0.0240 
5.0000 10.0684 0.5155 
3.0000 41.6055 0.1882 
3.0000 35.9806 0.1575 
3.0000 29.7165 0.3271 
3.0000 48.9494 0.3611 
3.0000 40.2096 0.2954 
3.0000 47.0974 0.1362 
5.0000 38.6038 0.1255 
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Subiect Rsa Corr(x:vl Tmax 
36 0.9966 -0.9983 2.5000 
37 0.8777 -0.9369 2.0000 
38 0.9684 -0.9841 4.0000 
39 0.9946 -0.9973 2.5000 
40 0.9991 -0.9995 2.0000 
41 Missina Missing 3.0000 
42 0.7792 -0.8827 3.0000 
43 0.9818 -0.9909 2.5000 
44 0.8269 -0.9093 3.0000 
45 0.9981 -0.9991 2.0000 
46 0.9076 -0.9527 3.0000 
47 0.9956 -0.9978 2.5000 
48 0.9835 -0.9917 2.5000 
49 0.7939 -0.8910 2.0000 
50 0.9966 -0.9983 2.5000 
51 0.9862 -0.9931 4.0000 
52 0.9991 -0.9995 2.0000 
53 0.9953 -0.9977 2.0000 
54 0.9908 -0.9954 3.0000 
55 0.9917 -0.9958 3.0000 
56 0.8709 -0.9332 2.5000 
57 0.9987 -0.9994 2.5000 
58 0.9908 -0.9954 2.5000 
59 0.9998 -0.9999 3.0000 
60 0.9972 -0.9986 4.0000 
61 0.9906 -0.9953 2.0000 
62 0.8819 -0.9391 2.5000 
63 0.9533 -0.9764 3.0000 
64 0.9983 -0.9991 2.5000 
65 0.9939 -0.9970 3.0000 
66 0.9925 -0.9963 3.0000 
67 0.9765 -0.9882 4.0000 
68 0.9400 -0.9695 4.0000 




































NCA Data - [C:\WINNONLN\AINHFIN.WDO] 
Final Parameters 
No. nnints Lambda z AUClast Lambda z 
3.0000 28.0481 0.2928 
6.0000 41.6397 0.1901 
3.0000 9.4552 0.1175 
4.0000 35.9865 0.3363 
3.0000 40.0115 0.2497 
0.0000 4.1392 Missing 
4.0000 27.6379 0.0963 
3.0000 31.2953 0.1116 
4.0000 12.6969 0.0805 
4.0000 25.7828 0.2906 
4.0000 19.4466 0.0712 
3.0000 17.6446 0.2356 
5.0000 19.9161 0.1200 
6.0000 15.1247 0.1048 
4.0000 35.4352 0.1967 
3.0000 16.3176 0.1320 
3.0000 14.2826 0.4186 
3.0000 18.4938 0.2391 
4.0000 31.0952 0.1696 
4.0000 16.8356 0.1944 
6.0000 8.6475 0.2441 
3.0000 25.9153 0.3232 
5.0000 30.1458 0.1301 
3.0000 43.5470 0.1385 
3.0000 22.6364 0.0907 
3.0000 27.4671 0.1431 
5.0000 19.3176 0.1607 
4.0000 17.6814 0.1687 
3.0000 27.8200 0.1139 
4.0000 24.1993 0.3043 
3.0000 16.3556 0.2176 
3.0000 23.5383 0.1558 
3.0000 24.2344 0.1645 
3.0000 23.9225 0.1258 
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Subiect Rsa Corr(x:v1 Tmax Cmax 
70 0.9610 -0.9803 1.5000 3.0287 
71 0.9824 -0.9911 2.5000 2.8488 
72 0.9310 -0.9649 2.0000 3.2405 
73 0.9996 -0.9998 2.0000 4.8396 
74 0.9739 -0.9869 2.5000 3.6075 
75 0.9794 -0.9896 1.0000 1.7971 
76 0.8946 -0.9458 2.0000 1.5083 
77 0.9963 -0.9982 2.0000 4.2072 
78 0.9865 -0.9932 3.0000 1.4845 
79 0.7833 -0.8851 4.0000 0.8465 
80 0.9637 -0.9817 3.0000 3.7632 
81 0.9897 -0.9949 3.0000 0.8602 
83 0.9449 -0.9721 2.5000 0.9407 
84 0.9678 -0.9838 4.0000 4.2546 
86 0.9959 -0.9979 2.5000 4.9645 
88 0.9934 -0.9967 2.5000 4.0895 
89 0.9822 -0.9911 2.5000 3.6715 
90 0.9483 -0.9738 4.0000 2.3775 
91 0.4713 -0.6865 2.5000 1.6664 
92 0.9489 -0.9741 3.0000 2.1026 
93 0.9972 -0.9986 2.0000 9.1369 
94 0.9986 -0.9993 2.5000 3.9057 
95 0.8274 -0.9096 2.0000 0.9869 
96 0.9786 -0.9893 2.5000 3.2947 
97 0.9981 -0.9991 3.0000 3.0693 
98 0.9350 -0.9669 2.0000 4.0603 
99 0.9892 -0.9946 2.5000 3.3970 
100 0.9553 -0.9774 2.0000 5.5218 
101 0.9449 -0.9720 3.0000 3.1051 
102 0.9897 -0.9948 2.5000 0.5430 
103 0.9954 -0.9977 2.5000 3.2262 
104 0.9982 -0.9991 2.5000 4.5941 
105 0.7838 -0.8853 2.5000 3.3869 
107 0.9510 -0.9752 4.0000 2.2800 
NCA Data - [C:\WINNONLN\AINHFIN.WDO] 
Final Parameters 
No. nnints Lambda z AUClast Lambda z 
7.0000 11.8533 0.1799 
5.0000 11.9505 0.2312 
6.0000 18.2674 0.1629 
3.0000 26.3464 0.2045 
4.0000 20.2505 0.2082 
7.0000 11.1731 0.0617 
6.0000 8.7867 0.0753 
3.0000 22.8872 0.2715 
3.0000 6.5520 0.1004 
3.0000 5.2597 0.0594 
5.0000 18.1413 0.1643 
4.0000 5.3930 0.0314 
3.0000 4.0420 0.0933 
3.0000 25.6940 0.1526 
5.0000 24.3160 0.2522 
3.0000 21.6544 0.2275 
3.0000 21.4347 0.1431 
3.0000 13.1346 0.1322 
3.0000 8.1682 0.0177 
3.0000 13.0678 0.1804 
3.0000 55.1417 0.1296 
3.0000 20.8572 0.2308 
5.0000 5.5108 0.0542 
5.0000 14.8998 0.2899 
3.0000 16.7648 0.1835 
5.0000 13.9579 0.7169 
5.0000 15.0352 0.2783 
3.0000 23.2397 0.3507 
4.0000 18.7670 0.1626 
3.0000 3.3283 0.1137 
5.0000 16.8412 0.1762 
3.0000 21.8543 0.2556 
6.0000 15.4484 0.2988 
3.0000 14.2757 0.1898 
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Subiect Rsa Corr(x:v) Tmax 
108 0.9510 -0.9752 4.0000 
109 0.9894 -0.9947 1.5000 
110 0.9885 -0.9942 3.0000 
111 1.0000 -1.0000 3.0000 
112 0.9877 -0.9939 3.0000 
113 0.9971 -0.9985 2.5000 
114 0.9985 -0.9993 4.0000 
115 0.9537 -0.9766 2.0000 
116 0.9997 -0.9998 3.0000 
117 0.9942 -0.9971 4.0000 
119 0.8204 -0.9058 4.0000 














NCA Data - [C:\WINNONLN\AINHFIN.WDO] 
Final Parameters 
No. noints Lambda z AUClast Lambda z 
3.0000 14.2757 0.1898 
3.0000 20.0806 0.2754 
3.0000 25.2228 0.2255 
3.0000 18.9742 0.1916 
3.0000 5.8745 0.0637 
3.0000 20.2242 0.1659 
3.0000 5.8170 0.0767 
3.0000 7.9710 0.0341 
3.0000 15.4547 0.2254 
3.0000 8.0476 0.1095 
3.0000 17.6252 0.0988 
3.0000 21.4205 0.2899 
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ELIMINATION AND FORMATION RA TE CONSTANTS 
Table A. The calculated rate constants for each individual in the study 
Subject No. Elimination Rate Constant Formation Rate Constant l Phenotype 
{h-1) (h-1) 
1 0.1993 -0.3802 Rapid 
2 0.1738 -1.1371 Intermediate 
3 0.1459 -1.1475 Intermediate 
4 0.2058 -0.7243 Rapid 
5 0.2543 -1.526 Intermediate 
6 0.2130 -0.3162 Intermediate 
7 0.2317 -1.342 Intermediate 
8 0.2183 -0.7809 Intermediate 
9 0.2598 -0.5205 Intermediate 
10 0.1706 -1.245 Rapid 
11 0.3356 -0.8204 Intermediate 
12 0.2238 -1.113 Slow 
13 0.1570 -1.535 Slow 
14 0.1431 -0.2632 Slow 
15 0.1337 -1.085 Rapid 
16 0.2632 -0.4472 Intermediate 
17 0.2814 -0.9405 Intermediate 
18 0.2483 -2.087 
19 0.2487 -1.317 Intermediate 
20 0.1767 -0.2260 Slow 
21 0.2186 -1.182 Rapid 
22 0.2001 -1.248 Slow 
23 0.1290 -0.4930 Rapid 
24 0.2499 -1.621 Intermediate 
25 0.2464 -0.8516 Intermediate 
26 0.1612 -0.1302 Slow 
27 0.5050 -2.148 Slow 
28 0.2761 -1.928 Rapid 
29 0.2766 -1.907 Intermediate 
30 0.3226 -1.336 Rapid 
31 0.2763 -0.7540 Rapid .. 
32 Excluded 
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33 0.3705 -0.3274 j Rapid 
34 0.2776 -0.7690 Intermediate 
35 0.2592 -0.7753 Rapid 
36 0.2919 -0.4296 Rapid 
37 0.2757 -0.9283 Rapid 
38 0.1755 -1.354 Slow 
39 0.2077 -1.187 Rapid 
40 0.2546 -0.9048 Rapid 
41 0.1739 -0.2959 Slow 
42 0.1777 -0.8032 Intermediate 
43 0.1345 -0.3266 Rapid 
44 0.1766 -0.7473 Slow 
45 0.4388 -0.6121 Rapid 
46 0.2380 -1.419 Intermediate 
47 0.1786 -0.8219 Intermediate 
48 0.2140 -1.035 Intermediate 
49 0.1551 -1.664 Intermediate 
50 0.2852 -0.6811 Rapid 
51 0.1960 -0.9851 Intermediate 
52 0.1876 -2.112 Intermediate 
53 0.2154 -0.6509 Rapid 
54 0.1570 -1.202 Rapid 
55 0.2760 -1.423 Intermediate 
56 0.2689 -0.2608 Slow 
57 0.2730 -1.018 Rapid 
58 0.3094 -1.061 Intermediate 
59 0.2353 -0.9873 Rapid 
60 0.2163 -1.566 Intermediate 
61 0.1675 -0.7170 Rapid 
62 0.2202 -1.131 Intermediate 
63 0.1866 -0.3769 Intermediate 
64 0.1392 -0.2033 Intermediate 
65 0.3020 -0.06426 Rapid 
66 0.2329 -0.9143 Intermediate 
67 0.2260 -1.882 Intermediate 
68 0.2389 -1.114 Intermediate 
69 0.1828 -1.210 
J 70 0.2573 -1.972 Slow 
71 0.1369 -0.5392 Intermediate 
72 0.2714 -0.2927 Intermediate 
73 0.3473 -0.3955 Intermediate 
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74 0.3335 -0.2478 Rapid 
75 0.2255 -1.079 Slow 
76 0.1390 -1.022 Slow 
77 0.2031 -0.02336 Rapid 
78 0.1449 -1.262 Slow 
79 0.1052 -1.459 Slow 
80 0.2460 -0.6967 Rapid 
81 0.1875 -1.839 Slow -82 Excluded 
83 0.1276 -2.631 Slow 
84 0.1891 -0.6403 Intermediate -85 Excluded 
86 0.2027 -0.7500 Rapid 
87 Excluded -88 0.3033 -1.055 I Rapid 
89 0.1911 -0.7490 Intermediate 
90 0.1947 -0.7518 Intermediate 
91 0.1778 -0.7767 Slow 
92 0.1825 -1.090 Intermediate 
93 0.1671 -0.8039 Intermediate 
94 0.3156 - Intermediate 
95 0.2177 -0.3629 Slow 
96 0.1968 -0.2908 Rapid 
97 0.2832 -1.641 Intermediate 
98 0.2751 -0.9807 Intermediate 
99 0.2583 -0.5087 Rapid 
100 0.5137 --0.7898 Intermediate 
101 0.2104 -0.2447 Intermediate 
102 0.1210 -0.6418 Intermediate 
103 0.1917 -0.4282 Intermediate 
104 0.1953 -1.024 Rapid 
105 0.2652 -1.247 Rapid 
106 Excluded 
107 0.2518 -0.2734 Intermediate 
108 0.2201 -0.8673 Intermediate 
109 0.2472 -1.148 Intermediate 
110 0.2038 -0.5835 Rapid 
111 0.2723 -0.7291 Rapid 
112 0.1442 -1.169 Slow 
113 0.2366 -0.5812 Intermediate 
114 0.1554 -0.9611 Slow 
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115 0.1509 -0.4583 Slow 
116 0.2419 -0.6747 Intermediate 
117 0.1860 -0.0630 Slow 
118 Excluded 
119 0.1987 -0.7708 Intermediate 
120 0.2545 -1.111 Rapid 
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APPENDIX V 
INDIVIDUAL PATIENT DETAILS 
Table B. Individual patient details 
Subject Age Weight Gender Race HIV Status 
Number @2 months 
001 50 45.1 F C -
002 22 43.2 F C -
003 24 37.9 F C -
004 33 46.9 F B + 
005 50 60 M C -
006 26 68 M C -
007 31 46 M C + 
008 21 33.4 F C -
009 36 46.4 F C -
010 20 48.5 F C -
011 21 46 F C -
012 31 38.5 F C -
013 19 50 M C -
014 31 66.3 M C + 
015 71 35.1 F C -
016 39 52.5 F C + 
017 56 39.4 F C -
018 47 48 F C -
019 36 38.2 F C + 
020 35 - M w + 
021 - - F C 0 
022 31 55.4 F C -
023 63 55.1 M C -
024 22 39.5 F B + 
025 51 42 F C + 
026 40 50 M C -
027 41 41.4 F C -
028 26 50 F C -
029 22 28.5 F B -
030 27 37.5 F C -
031 42 30.6 F C -
033 33 48.7 F C -
034 71 40.4 F C -
035 - - M C -
036 35 45.4 F C -
037 28 46.1 F C -
038 38 51.3 F C -
039 36 - F C -
040 26 50.6 F C -
041 57 60 M C -
042 30 44 M B + 
043 59 47 M C + 
044 - - F C -
045 37 37.2 F C -
046 37 43 M C -
047 30 47 M C -
048 35 53 M C -
Appendices 159 
049 22 54 M B + 
050 55 31.1 F C -
051 40 54 M C -
052 47 46 M C -
053 34 50 M C -
054 23 47.5 F B + 
055 31 46.6 F C -
056 39 30 F C -
057 29 40.6 F C -
058 22 37.4 F C -
059 45 39 F C -
060 35 36 M C -
061 48 45 M C -
062 31 46 M C -
063 43 52 M C -
064 40 85.5 F C -
065 26 - F C -
066 45 49 M C -
067 39 40 M C -
068 22 36 M C -
069 40 47 M C -
070 33 42 M C -
071 61 41.3 F C -
072 42 50.8 F C -
073 21 35.7 F C -
074 18 43.9 F C -
075 33 40.9 F C -
076 40 53 M C -
077 28 52 M C -
078 39 56 M C -
079 35 47 M C -
080 43 59.5 F C -
081 41 51 .8 F C -
083 55 52 M C -
084 46 46 M C -
086 28 40.1 F C -
088 36 36 M C -
089 48 44 M C -
090 26 49 M C + 
091 28 37.5 M C -
092 27 68.5 M B -
093 37 35.7 F C -
094 35 34 F C -
095 42 48.5 F C -
096 32 60.9 F C -
097 20 45.8 F B -
098 - - F C -
099 44 60.3 F C -
100 - - M -
101 42 46.5 M C -
102 18 49 F C -
103 30 60 M C -
104 30 52.8 F C -
105 23 53.7 F C -
107 58 36.5 F C -
108 58 43.4 F C -
109 26 46.8 F C -
110 44 41.5 F C -
111 50 41 M C -
Appendices 160 
112 53 68 M C -
113 58 50 M C -
114 22 50 M C -
115 - - M C -
116 19 50 M C -
117 21 46 M B -
119 50 - M C -
120 40 37 M C -
